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, ABSTRACT
This epidemiological study investigated the proposed relationship between three parameters
of thyroid function - thyroxine (T4)' triiodothyronine uptake (T3U) and thyroid stimulating
hormone (TSH), and various diseases in a population ofN.8.W. children ofvarying age, who
underwent blood screening for thyroid function at the Royal Alexandra Hospital for Children
between 1980 and 1990. Age, sex, puberty and year ofdiagnosis were identified as potential
confounders in the study and various measures taken to control for these factors in the
analysis. The study population was divided into two broad categories: patients aged less than
3 years ofage and, patients aged 3-18 years ofage. The main analysis concentrated on the 3-
i8,year age group. A Short Stature diagnostic group was selected as a control group in this
-category. As the diagnostic groups identified varied in normality, the Wilcoxon Rank Sum
Test was used for significance testing of the data. Seventy-eight separate diagnostic groups
were identified in patients aged 3-18 years. Twenty-one diagnostic groups showed a
statistically significant mean difference (p < 0.05) for T4 between the cases and the control
group. Ofthese, the following diagnostic groups were selected for analysis and found to have
a significantly low T4 compared to the control group: Selected Diabetes, Thalassaemia,
Growth Hormone Deficiency, Anorexia Nervosa, Acute Lymphoblastic Leukaemia, various
Psychological disorders and Cystic Fibrosis. The following diagnostic groups were found to
have a significantly high T4 compared to the control group: Obesity, Deafuess, Failure to
Thrive, Slipped Epiphyses, Turner's Syndrome and Juvenile Chronic Arthritis. These groups
were stratified by sex and puberty (3-11 years and >11-18 years) and similarly analysed. A
further analysis was performed in order to produce an odds ratio. These diagnostic groups
seemed to affect thyroid function in either of three different ways. Conditions affecting the
thyroid gland directly were reflected in the results for T4. Conditions affecting protein
binding mechanisms were reflected in the results for T3U and conditions which affect the
hypothalamic-pituitary axis were reflected in the results for TSH. The literature generally
supported the findings ofthis study.
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INTRODUCTION
Between 1980 and 1990, the results of thyroid testing of patients at the Royal
Alexandra Hospital for Children (RAHC) in Camperdown, Sydney were recorded in
a log book by Ms. Mary O'Halloran and occasionally Mrs. Fay Wood who performed
the thyroid function tests during this period. These data included: the date of the
sample, patient name, diagnosis, whether or not the patient was on treatment at the
time and values for thyroxine (T4), triiodothyronine uptake (T3U) and thyroid
stimulating hormone (TSH) on patients of varying age. The information was stored
using an alphabetical system so that all patients whose surnames began with the
letter "A" were stored in the "A" section of the log book and so on. The information
in the log book became the basis ofthis epidemiological study. These data were then
entered onto a computerised database according to pre-determined criteria and
analysed using varying statistical methods.
xi
AIM
The aim of this study was to investigate the relationship between thyroid hormone
levels and various diseases in a population ofN.S.W. children who underwent blood
screening for thyroid function but who were subsequently shown not to have thyroid
disease. Seventy-eight separate diagnostic groups were identified in patients aged
3-18 years. Ofthese, the main diseases investigated were Short Stature, Selected
Diabetes, Thalassaemia, Growth Hormone Deficiency, Anorexia Nervosa, Acute
Lymphoblastic Leukaemia, various Psychological disorders, Cystic Fibrosis, Obesity,
Deafness, Failure to Thrive, Slipped Epiphyses, Turner's Syndrome and Juvenile
Chronic Arthritis.
xii
CHAPTERl
BACKGROUND
The General Role of Thyroid Hormones
The thyroid gland secretes tetraiodothyronine or thyroxine (T4) and small amounts of
triiodothyronine (T3)' The thyroid hormones have three principal effects on the body:
a} regulation ofmetabolism,
b) regulation ofgrowth and development, and
c) regulation ofthe activity ofthe nervous system (Tortora & Anagnostakos, 1987).
With respect to regulation ofmetabolism, the thyroid hormones stimulate virtually
all aspects ofcarbohydrate and lipid metabolism in most cells ofthe body. They also
increase the rate ofprotein synthesis. The thyroid hormones also help to regulate
tissue growth and development, especially in children. Deficiency ofthe hormones
during foetal development can result in fewer and smaller neurons, defective
myelination ofaxons and mental retardation. During the early years of life,
deficiency ofthe hormones results in short stature and poor development ofceI'ta:in
organs and is required for normal growth and maturation in children (Wyngaarden,
& Smith, 1988). The thyroid hormones also increase the reactivity ofthe nervous
system which results in increased blood flow, increased blood pressure, increased
motility ofthe gastrointestinal tract and increased nervousness.
Regulation ofThyroxine Levels in the Blood
The normal thyroid gland produces about 85 micrograms ofT4 daily, with the
normal range for T4 being 65·180 nmoIIL (> 3 years ofage). About 80 per cent ofT3
is produced from conversion ofT4 to T3 in peripheral tissues. The remaining 20 per
cent ofT3 arises from direct thyroid gland secretion (Middlesworth, 1986). The
regulation ofthe secretion ofthyroid hormones is shown in Figure 1.1 and is
stimulated by several factors. IfT4 levels in the blood fall below normal, or the
metabolic rate decreases, chemical sensors in the hypothalamus which monitor the
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levels ofT4 in the blood, stimulate the hypothalamus to secrete thyrotropin releasing
factor (TRF), a regulating factor. TRF acts on the pituitary gland to secrete thyroid-
stimulating hormone (TSH) into the blood. TSH then stimulates the thyroid to
release thyroid hormones until the metabolic rate returns to normal. Conversely, if
T4 levels in the blood are high, then TRF production is reduced which leads to
reduced TSH and subsequent lowering ofT4 until blood levels return to normal.
Conditions that increase the body's need for energy - a cold environment, high
altitude, pregnancy - also trigger this feedback regulatory system and increase the
secretion ofthyroid hormones. Thyroid activity can be inhibited by a number of
other factors including large amounts ofcirculating oestrogens, other sex hormones,
and ageing (Tortora & Anagnostakos, 1987).
Thyroid hormones in plasma exist in two forms, free and protein bound. Although
only about 0.02 per cent oftotal plasma T4 and 0.3 per cent ofplasma T3 are free, it
is the free hormone concentration that is maintained constant by the feedback
regulatory system and that appears to parallel the rate ofcellular uptake ofthese
hormones. (Wyngaarden, & Smith, 1988). It is, therefore, the free hormone
concentration that determines the thyroid status irrespective ofthe total plasma
concentration. The delivery system for the thyroid hormones includes a set of
circulating transport proteins that vary widely in concentration and affinity for
thyroid hormone (Robbins, cited in Braverman & Utiger, 1991). The net result is
more than 99 per cent ofthe circulating hormone is protein-bound but can be
liberated with great rapidity for entry into cells. Thyroid-binding globulin (TBG) is
responsible for much ofthe immediate delivery ofT4 and T3 into the cells and
carries about 70 per cent ofthe circulating T4 and T3 by virtue ofits high affinity. It
has no other known physiological function (Robbins, cited in Braverman & Utiger,
1991). Other plasma proteins carrying thyroid hormones are albumin and
transthyretin, but to a much lesser extent than TBG.
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Figure 1.1 Regulation of the secretion of thyroid hormones
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(adaptedfrom Tortora &Al1agnostakos, 1987)
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Measurement of Thyroid Hormone
Measurements oftotal thyroid hormone concentrations utilize radioimmunoassay
(RIA) techniques and measure both bound and free hormones. These include
measurements ofT4 and T3. The similar binding characteristics ofT4 and T3 allow
the calculation ofa free T4 and free T3 index from the product ofthe T3 uptake ratio
(T3U) and total T4 or total T3' Results for T3U measurement are not an indicator of
T3 directly, but offree T4. The resulting free honnone index is effective in most
clinical settings. The free hormone fraction can be measured directly, using
equilibrium dialysis or ultrafiltration methods that utilize membranes that allow only
free hormone to pass through. These methods are rarely needed for clinical
diagnosis. Serum TSH is measured by RIA and may be the most sensitive indicator
ofthyroid status in nonthyroidal illness (Middlesworth, 1986). At the RARe, RIA
was used for both T4 and TSH measurement. T3U was measured in a resin uptake
test.
Serum Thyroid Hormone levels during Childhood
The variations in serum thyroid hormone and TSH concentrations during the first 20
years of life show serum T4 and T3 concentrations both decreasing gradually with
age. Serum T3U values remain relatively constant during childhood and adolescence,
indicating that the free T4 and free T3 fractions are stable during this time. The free
T4 and free T3 indices, however, decrease progressively, indicating a progressive
decrease in free T4 and free T3 concentrations with age. The decreases with age in
the ratios ofT3 to serum reverse T3 (rT3) and free T3 index to free rT3 index suggest
a progressive decrease in the relative conversion ofT4 to T3 with age during the first
15 years of life. (Fisher, cited in Braverman & Utiger, 1991). The mechanism for the
relative decrease in thyroid function is not clear as to whether it is mediated by a
decrease in TSH secretion or a decrease in thyroid gland responsiveness with age, or
both.
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Clinical Conditions
Hypothyroidism
Although patients listed with a diagnosis ofhypothyroidism have been excluded in
this study, hypothyroidism is one ofthe most common disorders ofthyroid function
and therefore worth noting.
Hypothyroidism is most often due to decreased thyroid hormone production by the
thyroid gland, known as primary hypothyroidism. It can also be due to decreased
thyroidal stimulation by TSH, due either to pituitary disease or to diminished
pituitary stimulation as a result ofa deficiency ofTRF. In this case it is known as
central, or secondary hypothyroidism because the hypothalamic-pituitary axis (HPA)
is affected. Tertiary hypothyroidism is a deficiency in TRF itself. The clinical
features ofhypothyroidism are largely independent of its cause. It affects both sexes
and all ages, although the age ofthe patient and the presence ofother diseases affect
the clinical presentation ofthe disease. It may be overt or subclinical; the latter is
most often defmed as increased serum TSH and normal T4 and T3 concentrations,
(Braverman & Utiger, 1991).
Generally, a paediatrician may request a thyroid function test on a child suspected of
having a thyroid problem. Thus children who are short, slow growing or slow to
develop etc., may be tested to ensure they do not have a thyroid-related condition
such as hypothyroidism. Conversely, children who are overactive and tall, or rapid to
develop are tested to ensure they do not have hyperthyroidism.
In some cases a thyroid problem is detected. The remaining children, for whom
thyroid disease has been excluded, are then essentially normal children who happen
to be at either extremes ofheight or weight when compared to the general population
for their age, for reasons which may be unrelated to thyroid hormone control
mechanisms. In this study, patients with known thyroid disease were excluded and
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the remaining major disease groups were investigated to see ifthere existed any
relationship between thyroid hormone levels and the diagnosis listed. Some ofthe
main disease groups encountered are outlined below.
Short Stature
In adolescence, short stature is defined as a height greater than 2.5 standard
deviations below the mean age for adolescence (Cohen & Rosenfeld, 1992). This can
have many causes, including multiple endocrine and systemic disorders. Ofthese,
normal variants are by far the most common, with endocrine disorders accounting
for only 10 percent ofthe cases ofshort stature (Cohen & Rosenfeld, 1992). In a
normal child ofshort stature, any ofthe following may be present: low birth weight,
(particularly under lOOOg), extreme prematurity, low mid-parental height, slight
build ofsiblings or other close relatives, normal growth velocity, no lack ofenergy
or responsiveness, observed normal interaction with parents and doctor, no
symptoms or signs ofpoor intake, malabsorption, or excess output,
(Marcovitch, 1994).
Insulin-dependent Diabetes Mellitus
Insulin-dependent diabetes mellitus (IDDM), or type 1 diabetes, is characterized by
an absolute deficiency ofinsulin due to a marked decline in the number of insulin-
producing beta cells in the pancreas, thought to be due to an autoimmune process.
IDDM usually develops during childhood, the peak incidence occurring at puberty,
(Craighead, cited in Rubin & Farber, 1988). Some cases develop during the first
years of life, and a fewer number develop after maturation. Fewer than 20% of
IDDM sufferers have a parent or sibling with the disease, so environmental factors
may play a role in the development ofthe disease (Craighead, cited in Rubin &
Farber, 1988).
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Thalassaemia
The term thalassaemia represents a group ofhereditary haemolytic anaemias,
resulting from a defect in the synthesis ofhaemoglobin, which produces extremely
thin and fragile erythrocytes (Tortora & Anagnostakos, 1987). The severity ofthe
resulting anaemia reflects both the degree ofcell destruction and the decreased
erythrocyte haemoglobin content. The specific thalassaemia syndromes are defined
by the globin chain part ofnormal haemoglobin A that is affected. In alpha-
thalassaemia, there is an abnormal synthesis ofthe alpha-chain, while in beta-
thalassaemia, synthesis ofthe beta-chain is affected (Bonner, cited in Rubin &
Farber, 1988). The distribution ofthalassaemia follows the malaria belt, and may be
attributable to the fact that certain thalassaemias enhance resistance to malaria.
Although the thalassaemia syndromes are found world-wide, specific forms occur
with high frequency in certain populations - notably in Mediterranean and Oriental
populations, with beta-thalassaemia and alpha-thalassaemia more common in these
respective groups (Nathan, cited in Beck, 1985).
Growth Hormone Deficiency
Growth hormone deficiency may be due to a number ofcauses including:
a) hypothalamic dysfunction, with impaired synthesis or secretion ofgrowth
hormone-releasing hormone (GHRH);
b) isolated growth hormone deficiency;
c) absent or low pituitary GH activity as a result ofabnormal GH molecules, or
d) unresponsiveness ofthe target organ to GH (Gould & Sommers, cited in Rubin &
Farber, 1988).
The molecular mechanism by which thyroid hormone permits normal GH secretion
is unclear. Retarded growth caused by hypothyroidism appears to result from
deficient secretion ofGH as well as from impaired action ofGH. Decreased GH
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secretion in hypothyroidism probably results from a direct effect ofthyroid hormone
deficiency on the pituitary itself and less likely from an effect on GHRH,
(Snyder, cited in Braverman & Utiger, 1991).
Anorexia Nervosa
Anorexia nervosa is a disorder characterized by loss ofappetite and altered eating
patterns. The subconsciously self-imposed starvation appears to be response to
emotional conflicts about self-identification and acceptance ofa normal adult sex
role (Tortora & Anagnostakos, 1987). The disorder is found predominantly in young
females and is one ofthe numerous disorders associated with low T3 syndrome.
Abnormalities in TSH secretion also occur in anorexia nervosa. Reduced basal and
stimulated serum TSH levels may be a consequence of increased serum cortisol
levels or a decreased response to TRF, and the mechanisms underlying this
phenomenon are complex (Scan/on, cited in Braverman & Utiger, 1991).
Acute LymphQblastic Leukaemia
Acute lymphoblastic leukaemia (ALL) is a malignant, clonal disorder ofthe bone
marrow lymphopoietic precursor cells. The cause is unknown. Typically, the onset is
acute or subacute in a previously healthy child or, less commonly in the adult. It is
predominantly a disease ofchildhood, 85% ofall cases occurring in children. It is
also the most common paediatric malignancy. In children, the incidence peaks
between 3 and 6 years ofage, with Caucasian males being most commonly affected.
(Banner, cited in Rubin & Farber, 1988). As a result ofmore effective therapy, an
increasing proportion ofchildren with the disease, now survive into adulthood and
some will be affected by residual side effects from their anti-Ieukaemic therapy.
Radiation and chemotherapy are capable ofproducing endocrine sequelae, which
include GH deficiency, disorders ofpubertal onset, thyroid failure and
hypothyroidism. Subtle primary hypothyroidism is relatively common in patients
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with ALL, particularly in those who have been treated with craniospinal irradiation
(Pasqualini et aI, 1991). In this study, patients who were listed as having
radiotherapy were excluded, as were those on chemotherapy.
P~hological Disorders
For the purposes ofthis study, a number ofdisorders were grouped to make a single
diagnostic group. A variety ofsevere psychiatric disturbances may be associated with
transient alterations in serum thyroid hormone levels (Spratt et al, 1982).
Characteristically, they take the form ofelevated serum total and free T4, variable
TSH and normal T3 concentrations. This pattern is most often found in manic-
depressive and other psychotic patients. Although the aetiology ofthese changes is
not known, they may represent the effects ofa briefperiod ofexcessive endogenous
TSH secretion secondary to disturbed hypothalamic function,
(Braverman & Utiger, 1991).
Cystic Fibrosis
Cystic fibrosis is a systemic genetic disease that affects essentially all exocrine
glands ofthe body and results in abnormal sweat electrolyte content and
hyperviscous secretions in the pancreas, biliary tract, and bronchial tree. Cystic
fibrosis is the most common clinically important autosomal recessive disorder in
Caucasian children, having an incidence of 1 in 2000 live births in this group,
(Millard & Lemen, cited in McAnamey et aI, 1992). More than 95 percent ofcases
have also been recorded in this group (Damjanov, cited in Rubin & Farber, 1988)
and 5 percent ofCaucasians carry the defective gene. Cystic fibrosis is also found in
children ofother backgrounds, including blacks and Hispanics, but is much less
common in these groups.
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Obesity
Obesity is defined as excess adiposity, that is, more than 25 per cent ofbody weight
composed offat in males and more than 30 percent in females (Arden, cited in
McAnarney et aI, 1992). Little is known about the aetiology ofobesity. There are
probably many different causes, some ofwhich may co-exist in a single individual.
Endocrine dysfunction can cause obesity. Hypothyroidism may be suspected when
accompanied by depression and sluggishness, and severe hypothyroidism can lead to
increased fat, but most ofthe excess bulk is actually oedema, which is lost with
thyroid hormone replacement therapy (Wyngaarden, & Smith, 1988). T4 regulates
the metabolism oflipids in the body and clinically low T4 levels are often associated
with high levels ofcholesterol and lipids in the blood.
Failure to Thrive
ltFailure to thrive" tends to be a descriptive term, not a diagnosis. There is no clear
agreement on definition but it is most commonly defined as "when his or her growth
fails to meet the potential for a child ofthat agell and " signs ofdevelopmental
retardation and ofphysical and emotional deprivation such as apathy, poor hygiene,
intense eye contact with people and withdrawing behaviour" as well as "disorders of
oral intake which may be manifested as anorexia, voracious appetite Of pica"
(Marcovitch, 1994). This description includes characteristics ofpsychosocial
deprivation, eating disorders and POOf growth, any combination ofwhich may be
present in an individual child.
Jaundice
An increased concentration ofbilirubin in the blood (>0.01 mg/ml) is termed
hyperbilirubinaemia. When the circulating bilirubin concentration attains levels
greater than 0.02 mg/ml, the skin and sclerae become yellow and the condition is
known as jaundice. Many conditions are associated with hyperbilirubinaemia. Over-
-10-
production ofbilirubin, interference with hepatic uptake or intracellular metabolism
ofbilirubin, and impairment ofbile excretion are all causes ofjaundice (Rubin &
Farber, 1988). Jaundice appears often in neonates. The most obvious evidence of
hepatic immaturity in neonates is the inability ofthe liver to conjugate and excrete
bilirubin, leading to jaundice. It is more pronounced in premature babies and usually
lasts longer in these infants than in those born at term. (Rubin & Farber, 1988).
Other liver functions are also not fully operational, but the deficiencies are easily
overcome with adequate medical support.
precocious .Pyberty
Precocious puberty is defined as the occurrence ofpuberty before the age of 8 years
in girls and 9 years in boys (Hardin & Pescovitz, cited in McAnarney et aI, 1992) and
is diagnosed on the basis ofclinical findings and laboratory results. The precocious
development is isosexual when the development is common to the phenotypic sex of
the individual and heterosexual when the development is characteristic ofthe
opposite sex. "True precocious puberty" is due to premature maturation ofthe
hypothalamic~pituitary axis (Wyngaarden, & Smith, 1988), and hence will affect
thyroid function.
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CHAPTER 2
METHODS
The methodological stages ofthe study are outlined in Figure 2.1.
Figure 2.1 Methods Flow Chart
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lEthics Proposal
Prior to commencing data entry. an application was made and approval granted from
the School ofCommunity Health, Faculty ofHealth Sciences Ethics Committee.
This was a standard application as used by the University ofSydney ethics
committee which is an NH&MRC (National Health and Medical Research Council) -
based committee. This ethics proposal was also made to the Royal Alexandra
Hospital for Children (RARC) via Dr. John Coakley, Head ofthe Clinical
Biochemistry Department. The application is contained in Appendix A. It was
decided that provided that confidentiality ofpatient information was maintained
throughout the study, there were no ethical problems in the use ofthese data.
Confidentiality was maintained by not removing at any time, the log boo~ or any
data containing patient names from the Clinical Biochemistry Department ofthe
RAHC~ by having only one data entry person (myself) and these data being entered
on site until completion. Once the data were entered and inclusion and primary
exclusion criteria determined, patients' names were deleted from the computer files,
prior to commencing statistical analyses.
Formulation of the Research Question and Study Type
The initial inspection ofthe raw data found that a number ofdifferent diagnoses and
almost complete thyroid function test results for each entry were available. It was
decided to investigate the relationship between the thyroid function test results for
each patient (specifically thyroxine) and the diagnosis listed as little was known in
this area at the time. This was done using the format ofan epidemiological case-
control study as the patients were identified first on disease status and then on
exposure (thyroid function).
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Hence the studyfactors for this study were the results ofthyroid function tests for
thyroxine (T4)' thyroid stimulating hormone (TSH) and triiodothyronine uptake,
(T3D) and the outcomefactors were the various diagnostic groups investigated. Thus
a case-control study consists ofa case group (diagnostic group) and a control group
(see Selection ofa Control Group). The research question was thus the relationship
between thyroid hormone levels and vari()us diagnostic groups in children having
thyroid function tests at the RAHC between 1980 and 1990.
Formation ofCase Groups
A list ofcodes used for computer entry ofdiagnoses with corresponding and
alternative meanings is contained in Appendix B. Preliminary statistical analyses
were conducted in patients aged 3-18 years only, (n =2998). Where more than one
diagnosis was given, these were converted to a single diagnosis where possible. In
the case where one diagnosis did not significantly interfere with the other, the
combination was converted to the most sigmficant diagnosis and then added to its
respective diagnostic group. A list ofthese conversions for patients aged 3-18 years
and less than 3 years is contained in Appendix C.
Diagnoses which were medically similar were then combined into single, larger
diagnostic groups which varied in sample size (n = 2 to n = 465). A list ofthe
diagnoses in these groups is contained in Appendix D, along with group reference
numbers. Individual diagnoses which could not logically be added to a diagnostic
group were not analysed and became part ofthe Miscellaneous group.
The main diagnosis ofeach diagnostic group was identified on the basis ofits effect
on the group when included and excluded in the calculation ofa p-value (results not
shown). lfthe diagnosis in question did not affect the p-value, it remained part ofthe
original diagnostic group. Ifthe diagnosis in question was responsible for an
observed effect, either due to its relative sample size or significant p-value, it was
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either analysed as a separate diagnostic group or used as the basis for the formation
ofa new diagnostic group~ as indicated by similar reference numbers (Appendix D).
All the decisions concerning the above conversions and combinations were done in
consultation with Dr. John Coakley and Dr. John Earl at the RARe.
Data Entry
Data entIy was commenced in October 1993 and completed in February 1994. Data
were entered onto Microsoft Excelfor Windows version 4.0 at the RARC. This
spreadsheet was used instead ofa standard database, due to the ease ofentering and
manipulating the data. Subsequent statistical analyses on these data were performed
using Excel and Spida version 6.06, a DOS-based statistical package developed at
Macquarie University, Sydney.
The raw data which were previously hand-recorded in a log book were arranged
alphabetically and were thus computer-entered. Individual codes were used for each
diagnosis as listed in Appendix B. Patient data were entered according to defined
inclusion and exclusion criteria and subject to further exclusion at the completion of
data entIy (as detailed below). After all exclusions were made the total number of
patients in the population for analysis was 4856 patients.
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Confounding
It is especially important to consider the phenomenon ofconfounding in a case-
control study as data on exposure are collected retrospectively. Confounding
involves the possibility that "the observed association between two groups may be
due in part or in total, to actual differences between the two groups under
comparison", (Hennekens & Buring, 1987). Thus the consideration ofconfounding is
important in the interpretation ofthe fmdings ofepidemiological studies, as
confounding can often lead to an erroneous interpretation ofthe true association
between exposure and disease and can even change the association ofan observed
effect (Hennekens & Buring, 1987).
Potential confounders identified in this study were thyroid disease, other diseases
which affect thyroid function, age, sex, puberty, year ofdiagnosis and some ofthe
combined diagnoses. These were identified as potential confounders because they
altered both the study factor (thyroid function) and outcome factor (diagnostic
groups), (Figure 2.2). Standard methods used to control for confounding are
randomization, matching, inclusion, exclusion and stratification. In this study
inclusion, exclusion, and stratification were strategies used in dealing with
confounding. (Figure 2.3). Primary and secondary exclusion criteria are presented in
Tables 2.2 and 2.3.
Figure 2.2 Confounding
STUDY FACTOR
(Exposure)
THYROID FUNCTION
CONFOUNDING
OUTCOME FACTOR
(Disease)
DIAGNOSTIC GROUPS
Figure 2.3 Controlling for confounding
I CONFOUNDING I
Options for data-identified confounding
INCLUSION EXCLUSION ISTRATIFICATION I
Inclusion <:titeri\'!.
as listed
Exclusion criteria
as listed
Under 3 yrs of age
Over 3 yrs of age
Pre - puberty
Post - puberty
SexAnalysis
Males
Females
Unknowns excluded
Inclusion Criteria
Any patient aged up to and including 18 years ofage attending the RARC for thyroid
function tests between 1980 and 1990 and recorded in the Clinical Biochemistry
Department log book.
Age stratification
The data were divided into two age groups: (i) under 3 years ofage and (ii) 3 years
and over to 18 years ofage. This division Was necessary due to the changing normal
range ofT4 levels in children by age. For children aged 3 years and over, there is a
single normal range for T4 and this is constant throughout this group (65-180
nmollL). These ranges are not absolute and for ease ofanalysis children aged 3 years
and over were analysed as a single group. For children aged less than 3 years ofage,
the ranges vary with age although there is a slight increase overall with age,
(Table 2.1).
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Table 2.1
Normal serum thyroxine ranges by age
Serum. thyroxine
(nmol/L)
130 -215
100 -215
110 - 215
95 -190
95-205
85 -180
75 -175
75 -180
65 -170
75-160
90 -155
65 *180
Age
o-2wks
2 -4wks
4-6wks
6-8wks
2-3mths
3 -4mths
4-6mths
6-9 mths
9 -12mths
1-2yrs
2-3yrs
>3yrs
(RARe, 1994)
For patients aged less than 3 years, the main diagnoses were examined graphically by
plotting the number ofcases per diagnosis versus age and the mean T4 per diagnosis
versus age. These results are presented in Chapter 5. It was decided that this would
be the extent to which the data for patients aged less than 3 years ofage would be
examined due to the following:
a) the lack ofa suitable control group in this population and,
b) the varying normal range for T4 in this group.
These factors would make further analysis ofthis group difficult. Subsequent
analyses were performed for patients aged 3 years and over.
Selection Bias
A case-control study, such as this, is one type ofepidemiological investigation in
which subjects are selected on whether the disease under investigation is absent
(controls) or present (cases) in them. Selection bias needs careful consideration in
case-control studies since the diseases have already occurred at the time ofsubject
selection and data on exposure is gathered retrospectively. Selection bias can occur
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whenever the inclusion ofcases or controls into the study depends in some way on
the exposure of interest (Hennekens & Buring, 1987). In this study the exposure is
thyroid function and the disease is the list ofvarious diagnostic groups. In an attempt
to control for selection bias in this study, patients with known thyroid disease were
excluded.
RespOnse Rate Estimation
In order to obtain information concerning selection ofthe data, a subset ofthe data
were analysed for data on exclusions, i.e. response rate. Exclusions for the first letter
ofthe alphabet ("A") were documented as follows. Table 2.2 lists the number ofand
type ofentries excluded in each case from a total number ofentries. (n =447), prior
to the rest ofthe data entry and exclusion. The numbers shown in brackets are for
entries where "treatment" was listed as "nolI (except for primary exclusions 4 and 5)
and are mutually exclusive. The total number ofprimary exclusions for the letter "A"
data entry equalled 221 (49.4%). These primary exclusion criteria were then used for
subsequent data entry. Thus it is estimated that 50 per cent ofthe total data were
excluded overall, primarily due to missing data.
At the completion ofeach letter ofdata entry, the data were sorted and duplicate
entries deleted by comparing the name and age at the date of sample~ leaving only
the first chronological entry for the purposes ofthis analysis. Those entries of
unknown sex were checked against later computerised laboratory results (where
available) in the Department ofClinical Biochemistry at the RARC, which included
the sex ofthe patient. Ifa log book entry could be positively identified with a more
recent computerised record by matching both the name and date ofbirth with the log
book entry ofthe patient's age at the date the sample was taken, the patient's sex was
changed from "unknown" to" male" or "female" respectively. Ifno match was made
the patient's sex was left as "unknown". At the completion ofall data entry secondary
exclusions were made as detailed in Table 2.3.
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Table 2.2 Primary exclusion criteria*
1. The patient was over 18 years of age (2).
2. No information on age was given (5).
3. The patient is the parent of a child also tested, regardless of age (1).
4. Treatment (usually T4) was listed as uYes" (78).
5. No information on treatment was given (29).
6. The patient was listed as being on any drug or treatment including lithium,
growth hormone, chemotherapy and radiotherapy as these have potential
interactive effects with the thyroid hormones (32).
7. The patient was participating in a trial, as treatment here was uncertain (6).
8. The patient had only a first initial or "Baby" listed as a first name as sex could not be
determined from this information unless by diagnosis (2).
9. More than one surname was given (1),
10. No diagnosis was given (6).
11. Where the diagnosis was any of the following:
a) Any known thyroid disease, e.g. hypothyroidism, goitre (40).
b) Any cancer except AML and ALL (4).
c) Any transplant patient, as these patients would most likely have been on
drug therapy which may interact with the thyroid hormones (1).
d) "Post-disease" as only current disease was of interest in this study (5).
12. Follow-up to past disease or treatment (7).
*Numbers in brackets are used to calculate the response rate for a subset of the data
consisting of the letter "A"group, (n :::: 447). Total number of exclusions =221.
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Table 2.3 Secondary exclusion criteria*
1. Where no T4 result was listed (9).
2. Thyroxin-binding globulin (TBG) deficiency. Upon checking for any apparent
clinical reason for a low T4 result, those with TBG < 12 mg/L were eliminated,
where listed (10),
3. Familial TBG excess (TBG > 28 mg/L), where listed (2).
4. TBG malfunction, indicated by a T3U result of < 0.8 nmol/L and> 1.2 nmol/L,
where listed (139).
5. Nephrotic Syndrome, as this has been linked to a loss of protein (6).
6. Primary hypothyroidism indicated by a TSH level> 7.0 mUIL, where listed.
Therefore Short Stature due to primary hypothyroidism was also eliminated (166 of
3782 with TSH value listed).
7. Pituitary Axis Disease, as this may be linked to secondary hypothyroidism (1).
8. Hypothalamic DisorderlDisturbance, as this may be linked to secondary
hypothyroidism (3).
9. Where no definite diagnosis was listed or where the requesting physician was
uncertain of the diagnosis (where not excluded previously). These cases would be
unable to be placed in one diagnostic group for investigation and their inclusion
would lead to error in the final result (95).
10. Any neurological disorders remaining after previous eliminations as these
patients may be on treatment which may affect thyroid function tests.
A list of these disorders is contained in Appendix E (160).
*Numbers in brackets are used to calculate the response rate for the total study population,
(n=4856).
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Selection ofa control group
In a case-control study, it is often appropriate to choose a group representative ofthe
general population. As this control group is compared to other diagnostic groups, a
control group as similar to these groups as possible, but without the diseases
themselves, is required. In an attempt to identify an appropriate control group for the
various diagnostic groups selected, an overall review ofthe data was conducted:
Medically opposite diagnostic groups were identified in the data and compared.
against one another for T4' T3U and TSH by age and puberty (Tables 2.4 to 2.6).
Generally, the groups are not significantly different from one another, indicating the
original study population was fairly homogeneous. Although there are significant
results for T3U, the small sample sizes in the T3U data need to be considered here.
The Short Stature diagnostic group was seen as a possible control group. Short
Stature due to primary hypothyroidism was eliminated, so the remaining patients
were most likelyjust genetically short, which is unrelated to thyroid function. This
group was also not significantly different from the Tall Stature group. It had a large
sample size and this would serve to increase the power ofthe analysis when
comparing case groups to the Short Stature diagnostic group, as the probability ofa
more accurate result is increased with a larger sample size.
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Table 2.4a T4: Opposite diagnostic groups by sex
Ref Group No. per group MeanT4 p-value
(nmollL)
M F Total M F Total M F Total
1 SHORT STATURE 781 374 1155 120.6 126.8 122.6
-
.
-
SA TALL STATURE 19 44 63 129.3 1185 121.8 0.104 0.023 0715
3B WEIGBTGAIN 3 5 8 105.3 123.6 116.8
- - -
4C WEIGHT LOSS 13 18 31 128.8 111.2 118.6 0.090 0.213 0.839
7A PRECOCIOUS PUBERTY 13 46 59 125.2 1267 126.4
- -
.
18 PUBERTAL DELAY 29 10 39 116.8 1197 117.6 0.195 0.435 0.096
12A MENSTRUAL PROBLEMS 0 17 17 ~ 117.6 117.6
-
.
-
12B AMENORRHOEA 0 17 17
-
116.7 116.7
-
0787 0.787
17A ALOPECIA 8 13 21 128.6 120.1 123.3
- - -
17B HIRSUTISM 0 12 12 - 1185 118.5 - 0.821 0.492
Table 2.4b T4: Opposite diagnostic groups by puberty
Ref Group No. per group MeanT4 p-vaIue
(nmollL)
3-11 yrs >11-18yrs Total 3-11 yrs >11-18 yrs Total 3-11 yrs >11-18 yrs Total
1 SHORT STAtuRE 662 493 1155 124.6 120.0 122.6
- - -
SA TALL STATURE 38 25 63 127.2 113.5 121.8 0519 0.125 0.715
3B WEIGHT GAIN 0 8 8 . 116.8 116.8 - - .
4C ""TEIGHT LOSS 11 20 31 135.6 109.2 118.6
-
0.423 0.839
7A PRECOCIOUS PUBERTY 55 4 59 1277 lOOS 126.4 - - -
18 PUBERTAL DELAY 0 39 39 - 117.6 117.6
-
0.675 0.096
12A MENSTRUAL PROBLEMS 4 13 17 115.0 119.2 117.6
- -
-
12B AMENORRHOEA 0 17 17
-
1167 116.7
-
0.673 0.757
17A ALOPECIA 17 4 21 126.8 108.8 123.3 -
-
-
118 HIRSUTISM 1 11 12 134.0 117.1 118.5 0.671 0.377 0.492
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Table 2.5a TSHr Opposite dia~ostic:groups by sex
Ref Group No. per group MeanTSH p-value
(nmo1/L)
M F Total M F Total M F Total
1 SHORT STATURE 762 355 1117 276 273 275
- - -
5A TALL STATURE 14 35 49 2.94 2.50 2.63 0.591 0.459 0.596
3B WEIGHT GAIN 2 3 5 0.85 3.27 2.30
- - -
4C WEIGHT LOSS 5 10 15 2.34 1.69 1.91 0.281 0.187 0.864
7A PRECOCIOUS PUBERTY 13 36 49 3.01 2.19 2.41
- - -
7B PUBERTAL DELAY 24 10 34 2.53 277 2.60 0.547 0.156 0.343
12A MENSTRUAL PROBLEMS 0 12 '12
-
173 173 . . -
12B AMENORRHOEA O· 14 14
-
2.56 2.56 - 0.214 0.214
17A ALOPECIA 2 7 9 370 2.63 2J5/ -
- -
17B HIRSUTISM 0 '1 7
-
1.89 1.89 . - 0.416 0.235
Table 2.5b TSH: Opposite diagnostic groups by puberty
Ref Group No. per group MeanTSH p-value
(nmo1/L)
3-11 yrs >11-18yrs Total 3-11 yrs >11-18yrs Total 3-11 yrs >11-18 yrs Total
1 SHORT STATURE 635 482 1117 2.83 2.66 275
- -
.
SA TALL STATURE 31 18 49 2.88 2.19 2.63 0720 0.140 0.596
3B WEIGHT GAIN 0 5 5
-
2.30 2.30 - - .
4C WEIGHT LOSS 5 10 15 2.36 1.68 1.<J1
-
0.756 0.864
7A PRECOCIOUS PUBERTY 46 3 49 2.36 3.07 2.41
- - -
7B PUBERTAL DELAY 0 34 34 - 2.60 2.60 - 0.485 0.343
12A MENSTRUAL PROBLEMS 4 8 12 1.38 1.91 173
- - -
12B AMENORRHOEA 0 14 14
- 2.56 2.56 - 0.500 0.214
17A ALOPECIA '1 2 9 2.94 2.60 2.87
-
.
-
118 HIRSUTISM 1 6 7 5.50 1.28 1.89 0.681 1.000 0.235
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Table 2.6a l'3U: Opposite diagnosti<: groups by sex
Rei Group No. per group MeanT3U p-value
M F Total M F Total M F Total
1 SHORT STATURE 781 374 1155 0.97 0.96 0.97
- - -
SA TALL STATURE 19 44 63 0.94 0.95 0.95 0.064 0.268 0.034
3B WEIGHTGAlN 3 5 8 0.94 0.90 0.92 - - -
4C WEIGHT LOSS 13 18 31 O.W 0.98 0.98 0.164 0.030 0.008
7A PRECOCIOUS PUBERTY 13 46 59 0.96 0.95 0.95
- - -
7B PUBERTAL DELAY 29 10 39 0.98 0.94 0.97 0.293 0.803 0.191
12A MENSTRUAL PROBLEMS 0 17 17
-
8.35 8.35 - - -
12B AMENORRHOEA 0 17 17 - 0.96 0.96 - 0.209 0.209
17A ALOPECIA 8 13 21 0.97 0.97 0.97 - - -
17B HIRSUTISM 0 12 12
-
0.96 0.96
-
0.952 0.877
Table 2.6b T3U: Opposite diagnostic groups by puberty
Ref Group No. per group MeanT3U p-value
3-11 yrs >11-18yrs Total 3-11 yrs >11-18yrs Total 3-11 yrs >11-18yrs Total
1 SHORT STATURE 662 493 1155 0.96 0.97 0.97
- - -
SA TALL STATURE 38 25 63 0.93 0.98 0.95 0.001 0.356 0.034
3B WEIGHTGAlN 0 8 8
-
0.92 0.92
- - -
4C WEIGHT LOSS 11 20 31 1.0 0.98 0.98
-
0.020 0.008
7A PRECOCIOUS PUBERTY 55 4 59 1.0 0.95 0.95
- - -
7B PUBERTAL DELAY 0 39 39
-
0.97 0.97
-
0.297 0.191
12A MENSTRUAL PROBLEMS 4 13 17 1.03 0.98 8.35
- -
-
12B AMENORRHOEA 0 17 17 - 0.96 0.96 - 0.331 0.209
17A ALOPECIA 17 4 21 0.97 0.97 0.97
- - -
17B HIRSUTISM 1 11 12 0.90 O.W 0.96 0.339 0.947 0.877
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Analysis
Statistical Analysis
The steps taken in the investigation ofthe study and outcome factors are shown in
Figure 2.4.
Figure 2.4 Investigation ofstudy and outcome factors
DEFINITION OF CHARACTERISTICS OF THE STUDY POPULATION
Case and Control Groups:
* Histograms
* Shapiro--Wilk Test for normality
ANALYSIS OF CASE AND CONTROL GROUPS
Mean T4, T3U and TSH in case groups:
* Wilcoxon Test for significance
INITIAL FINDINGS
Statistically significant differences between case and control groups
Selected groups chosen for further analysis
ODDS RATIO CALCULATIONS
OR and 95% Confidence intervals calculated by the Cornfield method
*Median Split
* Quartile Split
As T4 levels were the main exposure or study factor investigated, the data were
initially inspected to see ifthey were normally distributed by plotting data
distribution by study factor (thyroid function) and outcome factor (diagnostic group)
and then these factors were stratified by age, sex, puberty and year ofdiagnosis.
Histograms were initially used to inspect the groups which varied in distribution
between normally and non-normally distributed data.
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Five ofthe thirteen groups were not nonnally distributed. This was confirmed by
applying the Shapiro~Wilk Test for normality. A value ofless than 0.95 here
indicates the data was not normally distributed (Table 2.7). Figures 2.5 and 2.6 give
examples ofhistograms for two groups from the entire population (Diabetes and
Developmental Delay) which exhibit nonnal and non~nonnal distribution
respectively.
Figure 2.5 Total population: Diabetes histogram.
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Figure 2.6 Total population: Developmental Delay histogram.
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In order to see ifthere was a relationship between study and outcome factors, the
mean T4, TSH and T3-U were compared for each diagnostic group to the control
group (Short Stature). As the diagnostic groups varied in distribution, the Wilcoxon
Rank Sum Test was used for significance testing ofthe data to produce a p-value.
Where a statistically significant mean difference (p < 0.05) between case groups and
the control group were found for T4' a further analysis was performed in order to
produce an odds ratio. This value represents. the risk ofa particular diagnostic group
having a higher or lower T4 value compared to the control group.
Diagnoses found to have a significantly different T4 from the control group were
then reported and stratified into low T4 and high T4 categories with a subsequent
analysis on TSH and T3U. Due to the nature ofthe age and sex confounding
described previously, the diagnostic groups in these categories were also stratified by
sex and then re-stratified into pre- and post-puberty groups and analysed. In the case
where only one-sided stratification was possible, Le. stratification into males or
females only, or into 3-11 years or>11-18 years groups only, due to either small
sample size or nature ofthe disease, these groups were compared against the
corresponding sub-group in the control (Short Stature).
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Table 2.7 Shapiro·Wilk test for normality
Ref Group T4 TSH T3U
1 SHORT STATURE (control) 0.987 0.938 0.979
Signific::antly low T4
2B SELECTED DIABETES 0.991 0.878 0.982
lOA THALASSAE:MIA 0.984 0.972 0.961
13A GROWTH HORMONE DEFICIENCY 0.946 0.945 0.930
4D ANOREXIA NERVOSA 0.970 0.943 0.944
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 0.980 0.958 0.862
11D ALL PSYCHOLOGICAL DISORDERS 0.970 0.817 0.902
4B CYSTIC FIBROSIS 0.948 0.948 0.983
Significantly high T4
3A OBESITY 0.976 0.944 0.970
18 DEAFNESS 0.887 0.962 0.987
4A FAILURE TO THRIVE 0.979 0.971 0.961
20B SLIPPED EPIPHYSES 0.936 0.930 0.934
14A TURNER'S SYNDROME 0.982 0.953 0.929
9A JUVENILE CHRONIC ARTHRITIS 0.921 0.960 0.899
Odds Ratio
Odds ratios at the 95% confidence level were calculated for patients aged 3 years
and over, using the Cornfield method. Epi Into version 5.01 was used to perform this
analysis. Odds ratios were calculated for sex and age stratified data in the above
groups on T4 levels only, in order to assess the risk ofa low or high T4 respectively
for each diagnosis.
Both median and quartile splits were calculated from the control group. The control
group data was divided into halfby the median for Short Stature (123 nmol/L) and
again into quartiles by the interquartile split and the number ofvalues in each of
these splits noted. The number ofvalues in each halfor quartile respectively for each
diagnostic group were then compared against the number ofvalues in each ofthese
splits for the control group.
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For example, from the Selected Diabetes diagnostic group a 2 x 2 table can be
constructed with the following data in order to calculate a median split on this group
(Figure 2.7):
Figure 2.7 .
Median odds ratio calculation for the Selected Diahete~ diagnostic group (case group) agaiust
Short Stature (control group).
Cell Number per cell
a The number ofcase values below the control median =279
b The number ofcontrol values below the control median =611
e The number ofcase values above the control median = 183
d The number ofcontrol values above the control median = 544
OddS Ratio calculation
OR = aL.c.
bid
ad
be
272 x 544
611 xI83
.l..llZ1§. = 1.357 = 1.4
111813
Stratification
The Obesity and Failure to Thrive pre- and post-pubertal groups were further sub-
stratified by sex in order to attempt to explain the earlier findings. This was possible
since the total number ofpatients in these sub-groups was sufficiently large enough
to allow for further statistical testing. However, only T4 and TSH groups were tested
here since data for T3U sub-stratification were insufficient to allow for further
testing.
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CHAPTER 3
GENERAL RESULTS
The data presented in the results section were analysed as per the general statistical
analysis protocol presented in Chapter 2. Initially, the characteristics ofthe general
population are presented for both case and control groups. Histograms ofthe total
study population and the control group were prepared using Excel. Each potential
confounder was investigated separately and is described below.
In this general overview, potential confounders ofage, sex, puberty and year of
diagnosis are analysed to see if they are confounders in this data set, i.e. do they
affect both the diagnostic state and thyroid function. An a priori assumption based
on clinical knowledge was made that different diagnostic states will be affected by
age and sex. Hence apost hoc data analysis on age and sex for each diagnostic group
is not presented here but an indication is represented by the number ofpatients
plotted by the confounding variable.
Characteristics of the Study Population
Overall age group representations are shown in Table 3.1 and Figures 3.1a and 3.tb.
The study population was split on age « 3 years ofage and 3-18 years of age), as age
is an interaction factor in this study. Interaction can be thought ofas when two
components ofa disease share a causal responsibility for that disease (Rothman,
1986). In this case, the varying normal T4 ranges in patients aged less than 3 years of
age compared to those aged 3 years and over, indicate that the two groups are
metabolically different and hence not a homogeneous population.
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It was decided to restrict the main analysis to patients aged 3 years and over, the
results ofwhich are presented in Chapter 4. The results for patients aged less than 3
years are presented separately in Chapter 5.
Figure 3.1a shows the number ofpatients tested by age group and Figure 3.1b the
mean T4 for each ofthese groups. All the T4 results listed are for total T4. Thyroid
testing ofchildren is most commonly requested for neonates and during puberty and
this is reflected here with the highest number oftests in these groups. There is a
general decrease in mean T4 with age as was expected.
Table 3.1
Total study population by age
Age Number MeanT4
(yrs) of patients (nmol/L)
<=1 621 153.9
>1-2 257 134.9
>2-3 193 134.7
>3-4 164 132.4
>4-5 182 129.4
>5 -6 145 129.1
>6-7 183 125.2
>7 -8 179 127.2
>8-9 200 125.1
>9-10 182 125.2
>11-12 292 123.2
>12 -13 272 118.4
>13-14 283 117.1
>14 -15 243 115.6
>15 -16 188 114.3
>16 -17 122 111.8
>17 -18 53 114.8
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Figure3.1a
Total study population: Number of patients by age
Total population: Number of patients per age group
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Puberty and Sex;
Data for puberty and sex are presented in Table 3.2. Differences occurred in the data
overall by sex and puberty. Differences also occurred upon stratification between
pre- and post-puberty groups and between males and females.
Figure 3.2a shows the number ofpatients, and Figure 3.2b the Mean T4 in the pre-
and post-puberty groups for both males and females and overall by sex. Figure 3.2b
shows a possible link between T4 1evels and puberty, especially pre- and post-
puberty, with a decrease in T4 1evels post-puberty for both males and females. It also
indicates a possible link between T4 1evels and sex, with females having a slightly
higher T4 than males in this population.
Table 3.2
Sex and puberty variations in T4
Sex/Age (yrs)
Males: 3-11
Males: >11 -18
All males
Females: 3 - 11
Females: >11-18
All females
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Number Mean T4
per group (nmoI/L)
779 124.82
775 116.45
2105 127.30
754 129.22
678 118.58
1912 129.91
Figure3.2a
Pre~ and post-puberty: Number of patients per age group, by sex
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y ~ar ofDiagnosis
The number ofpatients and the mean T4 per year ofdiagnosis for the total study
population and the control group are presented in Table 3.3 and Table 3,4
respectively.
Figure 3.3a shows an overall increase in the number ofpatients tested per year
between 1980 and 1990 in the total study population, as is expected. During 1980-
1985 the number ofpatients tested is fairly consistent from year to year with a slight
decrease in 1982. There appears to be a more consistent rise in the number of
patients tested during 1986-1990. Figure 3.3b shows the mean T4 for the total
population ofpatients tested during 1980-1990. It is known that the assay method did
not change over this period, but there was a change ofoperator performing the assay.
This is discussed further in Chapter 6.
Table3.S
Total study population:
Number of patients and Mean T4
per year of diagnosis
Year of Diagnosis Number MeanT4
of patients (nmollL)
1980 326 124.6
1981 326 124.8
1982 267 124.3
1983 328 122.5
1984 321 121.0
1985 292 123.5
1986 349 125.7
1987 385 132.2
1988 416 132.6
1989 476 131.5
1990 531 139.8
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Figure3.3a
Total study population: Number of patients per year of diagnosis
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As the control group showed similar trends in both the "number ofpatients tested per
year (Figure 3Aa) and the mean T4 per year ofdiagnosis (Figure 3Ab), it was
concluded that this would probably not influence the analysis and interpretation of
the results. A further analysis could compare only patients aged 3~18 years with the
control group, as this would give a better indication of the trends over time in this
age group.
Table 3.4
Short stature (control) group:
Number of patients and Mean T4
per year of diagnosis
Year of Diagnosis Number MeanT4
of patients (runol/L)
1980 95 115.9
1981 119 117.2
1982 106 117.1
1983 117 120.8
1984 93 121.3
1985 85 118.3
1986 86 119.8
1987 109 128.5
1988 130 126.3
1989 105 122.8
1990 110 137.8
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Figure3.4a
Short stature (control) group: Number of patients per year of diagnosis
Control Group: Number of patients per year of diagnosis
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Disease frequency
A breakdo"WIl ofthe frequency ofdiagnoses encountered in the total population are
tabulated separately for patients aged less than 3 years ofage (Appendix F) and for
patients aged 3-18 years (Appendix G). This is the frequency ofeach diagnosis as it
occurred after all exclusions and combinations described previously were made.
-40-
CHAPTER 4
RESULTS
Characteristics of the control group
A summary ofthe characteristics ofthe control group by confounding factors is
presented in Table 4.1. All the T4 results listed are for total T4. The overall mean T4
ofthe control group was 122.6 nmol/L which falls close to the median ofthe nonnal
range for T4 (65-180 nmol/L). The mean T4 values for males and females, and pre-
and post- puberty groups also approached the median. It is interesting to note that the
control group (Short Stature) had the highest number ofpatients ofany other
diagnostic group (n = 1155) and this subsequently helped to increase the power of
the analysis.
Table 4.1 Characteristics of the control group - Short Stature
Thyroid function Number of % total Mean Standard
test of patients Deviation
T4
M 781 67.6% 120.6 20.50
F 374 32.4% 126.8 22.13
3-11 yrs 662 57.3% 124.6 21.26
>11-18 yrs 493 42.7% 120.0 20.96
Group total 1155 100% 122.6 21.23
TSH
M 762 68.2% 2.76 1.47
F 355 31.8% 2.73 1.52
3-11 yrs 635 56.8% 2.83 1.52
>11-18 yrs 482 43.2% 2.66 1.43
Group total 1117 100% 2.75 1.49
T3U
M 781 67.6% 0.97 0.07
F 374 32.4% 0.96 0.06
3-11 yrs 662 57.3% 1.01 0.07
>11-18 yrs 493 42.7% 1.01 0.07
Group total 1155 100% 1.01 0.07
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As previously indicated in Chapter 3, sex and puberty are confounders and thus the
data are individually analysed, stratifYing the data for male, female, 3-11 years and
11-18 years groups respectively.
Distribution of thyroxine levels by cases and control
Seventy-eight separate diagnostic groups were identified in patients aged 3-18 years.
Twenty-one diagnostic groups showed a statistically significant mean difference for
T4' (p < 0.05), usirig the Wilcoxon Rank: Sum Test for non-normally distributed data,
(Table 4.2). Those that did not show a statistically significant mean difference for T4
compared to the control group are listed in Table 4.3.
Table 4.2 Initial T4 analysis by diagnostic group: Significant results
Ref. Diagnostic Group Number Mean T4 p - value
per group (nmoIlL)
1 SHORT STATURE GROUP (control) 1155 122.6 -
2A ALL DIABETES 465 116.5 0
2B SELECTED DIABETES 462 116.4 0
3A OBESITY 174 128.8 0
18 DEAFNESS 25 137.8 0.000
lOA THALASSAEMIA 52 113.1 0.001
4A FAILURE TO THRIVE 46 134.0 0.001
13A GROWTH HORMONE DEFICIENCY 50 114.0 0.002
HA ANXIETY 4 94.0 0.002
27 MISCELLANEOUS GROUP 217 127.6 0.003
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 20 106.7 0.003
4D ANOREXIA NERVOSA 17 104.5 0.003
13C ALL ENDOCRINE DISORDERS (non-thyroidal) 81 116.0 0.004
9D JUVENILE CHRONIC ARTHRITIS + ARTHRITIS 13 142.2 0.007
20B SLIPPED EPIPHYSES 9 138.3 0.009
14A TURNER'S SYNDROME 47 129.8 0.011
9B CONNECTIVE TISSUE DISEASE 20 136.3 0.011
9A JUVENILE CHRONIC ARTHRITIS 8 145.9 0.012
4G SHORT BOWEL SYNDROME 2 163.5 0.013
110 ALL PSYCHOLOGICAL DISORDERS 18 110.9 0.020
11B BEHAVIOUR DISORDER 3 %.0 0.025
4B CYSTIC FIBROSIS 32 112.6 0.037
N.B. Groups in bold selected for further analysis
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Table 4.3 Initial T4 analysis by diagnostic group: Non-significant results
Ref. Diagnostic Group Number MeanT4 p-vaIue
per group (nmoI/L)
8 DEVELOPMENTAL DELAY 47 129.2 0.061
21B HYPOGONADISM 6 135.0 0.090
lOC SELECTED BLOOD DISORDERS 12 132.6 0.137
20A DELAYED BONE AGE 6 136.3 0.144
19B ABDOMINAL PAIN 9 129.4 0.159
21A GYNAECOMASTIA 10 114.0 0.170
19E CONSTIPATION +ABDOl.\i!INAL PAIN+DIARRHOEA 20 127.0 0.189
9E SELECTED CONNECTIVE TISSUE DISEASE 12 129.9 0.193
7B PUBERTAL DELAY 39 117.6 0.216
7A PRECOCIOUS PUBERTY 59 126.4 0.223
23 RENAL DISORDERS 16 130.4 0.236
9C ARTHRITIS 5 136.2 0.238
14E CYSTINOSIS 6 138.3 0.242
4I MALABSORPTION 2 109.0 0.247
WC CONSTIPATION + ABOOl.\i!INAL PAIN 19 126.4 0.253
140 PRADER-WILU SYNDROME 8 113.9 0.256
12B ALL AMENORRHOEA 17 116.7 0.257
155 ACUTE MYELOBLASTIC LEUKAEMIA 5 132.0 0.261
4J POOR/SWW WEIGHTGAIN 2 107.5 0.264
4K MALNUTRITION 1 142.0 0.290
25A SYNCOPE 6 128.8 0.324
145 OOWN'S SYNDRo.ME 30 118.2 0.362
16C MALAISE 3 112.7 0.367
225 SWEATING 7 129.6 0.385
14F KLINEFELTER'S SYNDROME 1 139.0 0.404
12A SELECTEDMENSTRUAL DISORDERS 17 117.6 0.413
165 WEAKNESS 5 116.0 0.421
4C WEIGHTLa;s 31 118.6 0.432
24C NAUSEA + VOMITING 8 129.3 0.445
25D HEADACHES 6 119.2 0.463
19D DIARRHOEA 1 137.0 0.464
115 HIRSUTISM 12 118.5 0.484
13D SELECTED ENDOCRINE DISORDERS (non-thyroidal) 31 119.3 0.504
35 WEIGHT GAIN 8 116.8 0.520
55 ALL TALLSTATURE CONDmONS 77 121.5 0.576
245 Vo.MITING 5 130.0 0.595
16A LE1HARGY 45 124.4 0.596
26A ASTHMA 6 125.2 0.634
24A NAUSEA 3 128.0 0.639
22D TREMOR +SWEATING 15 125.6 0.684
5A TALLNESS 63 121.8 0.712
22C TREMOR/SWEATING 1 113.0 0.742
17A AWPECIA 21 123.3 0.743
6A TACCHYCARDIA 12 121.3 0.794
6B ARRHYTHMr.As 19 123.3 0.801
22A TREMOR 8 122.1 0.805
19A CONSTIPATION 10 123.7 0.819
4F THINNESS 5 125.8 0.823
14C NooNAN'S DISEASE 10 122.8 0.831
6C ALL HEART DISEASE 25 121.9 0.848
4E EATING DISORDER/DISTURBANCE 6 119.2 0.860
lOB ANAEMIA 7 119.4 0.876
10D HYPERTENSION 4 122.5 0.897
nc SELECTED PSYCHOL<:X;ICAL DISORDERS 11 121.1 0.903
13B CONGENITAL ADRENAL HYPERPLASIA 19 121.7 0.918
4H COEliAC DISEASE 2 120.5 0.983
16D LETHARGY +WEAKNESS +MALAISE 53 122.9 0.984
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Thirteen diagnostic groups ofinterest from Table 4.2 were then selected for further
analysis. The eight remaining diagnostic groups not selected for further analysis were
not analysed due to small sample sizes in some cases, making statistical analysis
unfeasible or because the disease giving the significant result in these groups was
selected for separate analysis. For example, group 13C (all non-thyroidal endocrine
disorders) contained Growth Hormone Deficiency (GHD) as one of its members
which was responsible for the significant result in this group. Hence GHD was
analysed as a separate diagnostic group (l3A) in the study.
The Selected Diabetes, Thalassaemia, Growth Hormone Deficiency, Anorexia
Nervosa, Acute Lymphoblastic Leukaemia, All Psychological Disorders and Cystic
Fibrosis diagnostic groups showed a significantly low T4 compared to the control
group. The Obesity, Deafness, Failure to Thrive, Slipped Epiphyses, Turner's
Syndrome and Juvenile Chronic Arthritis diagnostic groups showed a significantly
high T4 compared to the control group. These groups selected for analysis were
further investigated for differences in TSH and T3U levels and these results are
presented in Tables 4.4 to 4.6.
A4-
Table 4.4 T4: Statistical results by diagnostic group
Ref Group Number Mean p-value
per group Difference
inT4
1 SHORT STATURE (control) 1155 0.0 -
Mean T4 = 122.6 nmol/L
Significantly low T4
2B SELECTED DIABETES 462 6.2 0
lOA THALASSAEMIA 52 9.5 0.001
13A GROWTH HORMONE DEFICIENCY 50 8.6 0.002
4D ANOREXIA NERVOSA 17 18.1 0.003
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 20 15.9 0.003
lID ALL PSYCHOLOGICAL DISORDERS 18 11.7 0.020
4B CYSTIC FIBROSIS 32 10.0 0.037
Significantly high T4
3A OBESITY 174 --6.2 0
18 DEAFNESS 25 -15.2 0
4A FAILURE TO THRIVE 46 -11.4 0.001
20B SLIPPED EPIPHYSES 9 -15.7 0.009
14A TURNER'S SYNDROME 47 -7.2 0.011
9A JUVENILE CHRONIC ARTHRITIS 8 -23.3 0.012
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Table 4.5 TSH: Statistical results by diagnostic group
Ref Group Number Mean p-value
per group Difference
inTSH
1 SHORT STATURE (control) 1117 0.0
-
Mean TSH = 2.75 mU/L
Significantly low T4
2B SELECTED DIABETES 443 0.49 0
lOA THALASSAEMIA 48 -0.37 0.071
13A GROWTH HORMONE DEFIOENCY 47 0.05 0.786
4D ANOREXIA NERVOSA 14 0.39 0.407
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 18 -0.72 0.109
11D ALL PSYCHOLOGICAL DISORDERS 10 0.74 0.088
4B CYSTIC FIBROSIS 28 -0.73 0.003
Significantly high T4
3A OBESITY 139 0.10 0.586
18 DEAFNESS 4 0.60 0.503
4A FAILURE TO THRIVE 24 -3.29 0.055
20B SLIPPED EPIPHYSES 6 -0.88 0.170
14A TURNER'S SYNDROME 44 -0.70 0.002
9A JUVENILE CHRONIC ARTHRITIS 5 0.61 0.012
Table 4.6 T3U: Statistical results by diagnostic group
Ref Group Number Mean p-value
per group Difference
inT3U
1 SHORT STATURE (control) 1155 0.0 -
Mean T3U =0.97
Significantly low T4
2B SELECTED DIABETES 462 -0.04 0
lOA THALASSAEMIA 52 -0.03 0.008
13A GROWTH HORMONE DEFICIENCY 49 0.01 0.683
4D ANOREXIA NERVOSA 17 0.00 0.778
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 20 -0.03 0.603
llD ALL PSYCHOLOGICAL DISORDERS 18 -0.01 0.286
4B CYSTIC FIBROSIS 32 -0.01 0.483
Significantly high T4
3A OBESITY 174 0.04 0
18 DEAFNESS 25 0.01 0.459
4A FAILURE TO THRIVE 46 0.00 0.975
20B SLIPPED EPIPHYSES 9 0.03 0.134
14A TURNER'S SYNDROME 47 -0.01 0.841
9A JUVENILE CHRONIC ARTHRITIS 8 -0.03 0.190
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The above groups were sub-stratified by sex and age (pre- and post-puberty groups)
and re-tested. These results are presented below in Tables 4.7 to 4.9 and 4.10 to 4.12
respectively. For T4' the following diagnostic groups were significant when stratified
by sex and age:
Acute Lymphoblastic Leukaemia, except for females;
Growth Hormone Deficiency, the Psychological Disorders and Slipped
Epiphyses groups, except for the female and pre-pubertal subgroups in each;
Failure to Thrive, except for female and post-pubertal subgroups;
Juvenile Chronic Arthritis, except for male and post-pubertal subgroups;
Selected Diabetes and Thalassaemia, except for the pre-pubertal subgroup in
each;
Cystic Fibrosis, only in females;
Obesity, only in the pre..pubertal subgroup;
In Anorexia Nervosa and Turner's Syndrome, there were no males, and only the post-
pubertal subgroups were significant for each. In the Deafness group, there was no
post-pubertal subgroup, with all other Deafness subgroups significant for T4. As
these "missing" data are potential sex and puberty confounders, the stratified groups
were tested against the respective Short Stature sub-groups, e.g. Turner's Syndrome
(all females) was tested against Short Stature females. The results are presented in
Table 4.13.
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Table 4.7 T4: Statistical results by diagnosis and sex
Ref Group Number per group Mean Difference p -value
in T4
M F M F M F
1 SHORT STATURE (control) 781 374 0.0 0.0
- -
Mean T4 (nmol/L):
Males: 120.6
Females: 126.8
Significantly low T4
2B SELECTED DIABETES 211 251 5.9 9.0 0 0
lOA THALASSAEMIA 20 32 12.8 10.5 0.004 0.012
13A GROWTH~ORMONEDE~CmNCY 35 15 13.5 -3.3 0 0.897
4D ANOREXIA NERVOSA 0 17
-
22.3
-
0.001
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 14 6 17.7 11.3 0.001 0.510
11D ALL PSYCHOLOGICAL DISORDERS 10 8 17.8 5.8 0.003 0.606
4B CYSTIC FIBROSIS 14 18 8.5 13.9 0.246 0.028
Significantly high T4
3A OBESITY 60 114 -5.4 -3.5 0.096 0.Q71
18 DEAFNESS 13 12 -17.3 -11.0 0.001 0.040
4A FAILURE TO THRIVE 21 25 -11.2 -9.0 0.024 0.077
20B SLIPPED EPIPHYSES 4 5 -20.7 -9.2 0.036 0.230
14A TURNER'S SYNDROME 0 47 - -3.0 - 0.242
9A JUVENILE CHRONIC ARTHRITIS 4 4 -6.9 -37.5 0.406 0.008
Table 4.8 TSH: Statistical results by diagnosis and sex
Ref Group Number per group Mean Difference p-value
in TSH
M F M F M F
1 SHORT STATURE (control) 762 355 0.0 0.0
-
.
Mean TSH (mUlL):
Males: 2.76
Females: 2.73
Significantly low T4
2B SELECTED DIABETES 203 240 0.37 0.59 0 0
lOA THALASSAEMIA 19 29 -0.15 -0.53 0.631 0.045
13A GROWTH HORMONE DE~CmNCY 33 14 0.16 -0.21 0.552 0.723
4D ANOREXIA NERVOSA 0 14
-
0.37
-
0.479
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 12 6 -0.40 -1.37 0.485 0.067
110 ALL PSYCHOLOGICAL DISORDERS 4 6 -0.19 1.35 0.736 0.013
4B CYSTIC FIBROSIS 13 15 -0.44 -0.99 0.183 0.004
Significantly high T4
3A OBESITY 52 87 0.25 -om 0.211 0.672
18 DEAFNESS 3 1 0.33 1.43 0.883 0.265
4A FAILURE TO THRIVE 12 12 -0.58 -0.51 0.107 0.241
20B SLIPPED EPIPHYSES 1 5 1.16 1.69 0.505 0.057
14A TURNER'S SYNDROME 0 44 - -0.72 - 0.002
9A JUVENILE CHRONIC ARTHRITIS 3 2 1.36 -0.52 0.061 0.496
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Table 4.9 T3U: Statistical results by diagnosis and sex
Rei Group Number per group Mean Difference p-value
in T3U
M F M F M F
1 SHORT STATURE (control) 781 374 0.0 0.0
- -
MeanT3U:
Males: 0.97
Females: 0.96
Significantly low T4
2B SELECTED DIABETES 211 251 ..0.06 -0.03 0 0
lOA THALASSAEMIA 20 32 -0.06 -0.02 0.001 0.509
13A GROWTH HORMONE DEFICIENCY 34 15 0.01 -0.02 0.935 0.536
4D ANOREXIA NERVOSA 0 17
-
0.00 .. 0.647
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 14 6 -0.03 -om 0.286 0.455
11D ALL PSYCHOLOGICAL DISORDERS 10 8 -0.03 0.01 0.083 0.749
4B CYSTIC FIBROSIS 14 18 0.01 -0.02 0.574 0.098
Significantly high T4
3A OBESITY 60 114 0.04 0.04 0 0
18 DEAFNESS 13 12 -0.02 0.04 0.212 0.016
4A FAILURE TO THRIVE 21 25 -0.01 0.01 0.545 0.726
20B SLIPPED EPIPHYSES 4 5 0.05 0.01 0.084 0.721
14A TURNER'S SYNDROME 0 47 .. -0.01 .. 0.972
9A JUVENILE CHRONIC ARTHRITIS 4 4 -0.05 0.00 M59 0.998
Table 4.10 T4: Statistical results by diagnosis and puberty
Ref Group Number per group Mean Difference p-value
in T4
3-llyrs >U..18yrs 3-11 yrs >11-18yrs 3-11yrs >11-18yrs
1 SHORT STATURE (control) 662 493 0.0 0.0 ..
-
Mean T4 (nmol/L):
341 yrs: 124.6
>11-18yrs: 120.0
Significantly low T4
2B SELECTED DIABETES 155 307 2.4 6.6 0.414 0
lOA THALASSAEMIA 37 15 5.5 21.9 0.135 0
13A GROWTH HORMONE DEFICIENCY 22 28 4.6 10.7 0.299 0.001
4D ANOREXIA NERVOSA 4 13 -4.7 23.1 0.848 0.001
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 12 8 13.8 19.4 0.047 0.019
110 ALL PSYCHOLOGICAL DISORDERS 4 14 21.3 6.9 0.047 0.213
4B CYSTIC FIBROSIS 12 20 9.4 9.0 0.231 0.131
Significantly high T4
3A OBESITY 87 87 -10.9 -2.2 0 0.225
18 DEAFNESS 25 0 -13.2
-
0
-
4A FAILURE TO THRIVE 38 8 -12.5 0.6 0.001 0.742
20B SLIPPED EPIPHYSES 1 8 -3.4 -19.6 0.918 0.003
14A TURNER'S SYNDROME 26 21 -52 -9.8 0.161 0.024
9A JUVENILE CHRONIC ARTHRITIS 5 3 -32.2 ·7.7 0.008 0.490
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Table 4.11 TSH: Statistical results by diagnosis and puberty
Raf Group Number per group Mean Difference p- .value
in TSH
3·11 yrs >11-18 yrs 3-11yrs >11-18yrs 3·11 yrs >11-18yrs
1 SHORT STATURE (control) 635 482 0.0 0.0
- -
Mean TSH (mU/L):
3-11 yrs: 2.83
>11-18 yrs: 2.66
Significantly low 1'4
2B SELECTED DIABETES 149 294 0.34 0.50 0.005 0
lOA THALASSAEMIA 34 14 -0.04 -1.09 0.643 0.016
13A GROWTH HORMONE DEFICIENCY 20 27 0.13 -0.05 0.547 0.756
4D ANOREXIA NERVOSA 4 10 -0.42 0.65 0.338 0.111
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 10 8 -0.63 -0.83 0.369 0.154
110 ALL PSYCHOLOGICAL DISORDERS 4 6 0.65 0.76 0.449 0.115
4B CYSTIC FIBROSIS 10 18 -0.41 -0.96 0.262 0.002
Significantly high 1'4
SA OBESITY 70 69 0.03 0.14 0.976 0.536
18 DEAFNESS 4 0 0.68 - 0.427 -
4A FAILURE TO THRIVE 18 6 -0.50 -0.53 0.109 0.480
20B SLIPPED EPIPHYSES 1 5 -2.97 -0.55 0.069 0.369
14A TURNER'S SYNDROME 24 20 -0.85 -0.52 0.005 0.141
9A JUVENILE CHRONIC ARTHRITIS 2 3 -0.42 1.26 0.591 0.072
Table 4.12 T3U: Statistical results by diagnosis and puberty
Ref Group Number per group Mean Difference p-value
in T3U
3-11 yrs >U-18yrs 3-11 yrs >11-18 yrs 3-11 yrs >11-18yrs
1 SHORT STATURE (control) 662 493 0.0 0.0 .
-
MeanT3U:
3-11 yrs: 0.96
>11-18yrs:0.97
Significantly low 1'4
2B SELECTED DIABETES 155 307 -0.05 -0.04 0 0
lOA THALASSAEMIA 37 15 -0.02 -0.06 0.060 0.025
13A GROWTH HORMONE DEFICIENCY 21 28 0.02 0.01 0.569 0.817
4D ANOREXIA NERVOSA 4 13 0.00 0.01 0.743 0.939
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 12 8 -0.04 0.00 0.230 0.502
lID ALL PSYCHOLOGICAL DISORDERS 4 14 0.01 -om 0.988 0.307
4B CYSTIC FIBROSIS 12 20 0.02 -0.02 0.441 0.186
Significantly high 1'4
3A OBESITY 87 87 0.04 0.06 0 0
18 DEAFNESS 25 0 0.00
-
0.634
-
4A FAILURE TO THRIVE 38 8 0.01 -0.03 0.678 0.146
20B SLIPPED EPIPHYSES 1 8 -0.02 0.04 0.908 0.054
14A TURNER'S SYNDROME 26 21 -0.02 0.01 0.490 0.257
9A JUVENILE CHRONIC ARTHRITIS 5 3 -0.02 -0.43 0.541 0.167
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Table 4.13 Analysis of possible sub-group confounding
Ref Group Number per Mean difference p - value
group inT4
1 SHORT STATURE (control) - females 251
-
.
Mean T4 :::; 117.8 nmol/L
4D ANOREXIA NERVOSA 17 13.3 0.001
14A TURNER'S SYNDROME 47 -12.0 0.241
1 SHORT STATURE (control) - 3-11 years 662
- -
Mean T4 :::; 124.6 nmol/L
18 DEAFNESS 25 -13.2 0.001
In Table 4.13, the Anorexia Nervosa diagnostic group showed a significantly lower
T4 compared to control group females. Turner's Syndrome was not significantly
different from the control group females. The Deafuess diagnostic group showed a
significantly higher T4 compared to the pre-pubertal control group. These results are
discussed more fully within each diagnostic group in Chapter 6.
Odds Ratio
An odds ratio calculation was used in order to assess the risk of having a low or high
T4 with these diseases. Odds ratios were calculated for T4 values only, as T3U and
TSH had relatively small sample sizes in particular sub-group analyses. The results
ofmedian and quartile odds ratios calculations are presented in Tables 4.14 and
4.15. As in all epidemiological studies, these results do not prove a causal
relationship exists between T4 and the diagnostic groups studied. The odds ratios
estimate the probability ofhaving either a high or low T4 for each disease, compared
to the control group. These results do not indicate that a low or high T4 leads to any
ofthese diseases. The 95% confidence interval means that there is a 95% chance that
this estimate lies within the given range. Many ofthe estimates have wide
confidence intervals, indicating that the true odds ratio is very difficult to estimate.
Where no result is given, the odds ratio could not be calculated due to a zero value in
the formula (see Chapter 2), probably because of small sample sizes in some ofthe
quartile splits.
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Table 4.14 T4: Odds Ratios and 95% Confidence Intervals - Median Split
Ref Group Number OR 95%C.I.
per group
1 SHORT STATURE (control) 1155 1.00 -
Significantly low T4
2B SELECTED DIABETES 462 1.46 (1.16 - 1.83)
lOA THALASSAEMIA 52 2.32 (1.23 - 4.41)
13A GROWTH HORMONE DEFICIENCY 50 2.40 (1.25 - 4.66)
4D ANOREXIA NERVOSA 17 3.09 (0.92 - 11.41)
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 20 3.09 (1.04·9.78)
11D ALL PSYCHOLOGICAL DISORDERS 18 2.06 (0.71 - 6.19)
4B CYSTIC FIBROSIS 32 1.97 (0.89 - 4.39)
Significantly high T4
3A OBESITY 174 1.80 (1.27 - 2.54)
18 DEAFNESS 25 5.58 (1.82 - 19.16)
4A FAILURE TO THRIVE 46 2.22 (1.13 - 4.42)
20B SLIPPED EPIPHYSES 9 7.77 (0.99 - 166.12)
14A TURNER'S SYNDROME 47 2.07 (1.07 - 4.05)
9A JUVENILE CHRONIC ARTHRITIS 8 6.80 (0.84-147.46)
Table 4.15 T4: Odds Ratios and 95% Confidence Intervals - Quartile Split
Ref Group Number OR 95%C.I.
per group
1 SHORT STATURE (control) 1155 1.00
-
Significantly low T4
2B SELECTED DIABETES 462 2.34 (1.67 - 3.27)
lOA THALASSAEMIA 52 3.33 (1.40 - 8.15)
13A GROWTH HORMONE DEFICIENCY 50 2.96 (1.29 - 6.95)
4D ANOREXIA NERVOSA 17 4.79 (0.96 - 32.35)
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 20 10.64 (1.40 - 223.62)
110 ALL PSYCHOLOGICAL DISORDERS 18 4.79 (0.96 - 32.35)
4B CYSTIC FIBROSIS 32 2.13 (0.73 - 6.45)
Significantly high T4
3A OBESITY 174 1.69 (1.06 - 2.70)
18 DEAFNESS 25 7.52 (1.64 - 47.75)
4A FAILURE TO THRIVE 46 3.13 (1.17 - 8.85)
20B SLIPPED EPIPHYSES 9
- -
14A TURNER'S SYNDROME 47 2.00 (0.80 - 5.13)
9A JUVENILE CHRONIC ARTHRITIS 8
-
-
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Sub-stratification by puberty and sex
The Short Stature (control) pre- and post-puberty groups, further sub-stratified by sex
are presented in Table 4.16 below. The results ofthe Obesity and Failure to Thrive
pre* and post*puberty groups, further sub*stratified by sex and compared to the
control group, are presented in Tables 4.17 to 4.18 below.
For both the Failure to Thrive and Obesity groups, significant T4 results were noted
in the pre-puberty groups for both males and females. Although the TSH result for
Failure to Thrive approached significance in the total group, this was lost upon sub-
stratification. In the Obesity group, TSH was not significant in either ofthe
subgroups or in the whole group.
Table 4.16
Short Stature: sub*analysis by puberty and sex
Sub-group Number % total Mean Standard
per group Deviation
T4
Males 3-11 yrs 427 37.0% 122.6 21.02
Males >11-18 yrs 354 30.6% 118.2 19.62
Females 3-11 yrs 235 20.3% 128.1 21.27
Females>11-18 yrs 139 12.0% 124.5 23.40
Group total 1155 100% 122.6 21.23
TSH
Males 3-11 yrs 414 37.1% 2.85 1.49
Males >11-18 yrs 348 31.2% 2.66 1.45
Females 3-11 yrs 221 19.8% 2.79 1.59
Females>11-18 yrs 134 12.0% 2.63 1.40
Group total 1117 100% 2.75 1.49
T3U
Males 3-11 yrs 427 37.0% 0.96 0.07
Males>11-18 yrs 354 30.6% 0.97 0.07
Females 3-11 yrs 235 20.3% 0.96 0.06
Females>11-18 yrs 139 12.0% 0.97 0.06
Group total 1155 100% 1.01 0.07
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Table 4.17
Failure to thrive: sub-analysis by puberty and sex
SUb-group
T4
Males 3-11 yrs
Males >11-18 yrs
Females 3-11 yrs
Females >11-18 yrs
Group total
TSH
Males 3-11 yrs
Males >11-18 yrs
Females 3-11 yrs
Females>11-18 yrs
Group total
Table 4.18
Obesity: sub-analysis by sex and puberty
Number % total Mean Standard p - value
per group Deviation
17 37.0% 134.0 22.10 0.033
4 8.7% 122.5 26.89 0.833
21 45.7% 139.6 21.70 0.039
4 8.7% 116.3 22.22 0,386
46 100.0% 134.0 22.77 0.001
9 37.5% 3.36 1.11 0.206
3 12.5% 3.30 2.00 0.534
9 37.5% 3.30 1.60 0.280
3 12.5% 3.07 2.56 0.711
24 100.0% 3.29 1.50 0.055
Sub-group
T4
Number % total Mean Standard p - value
per group Deviation
Males 3-11 yrs
Males>11-18 yrs
Females 3-11 yrs
Females >11-18 yrs
Group total
TSH
23
37
64
50
174
13.2% 136.1
21.3% 119.7
36.8% 135.2
28.7% 124.0
100% 128.8
24.21
23.52
19.17
19.69
21.90
0.009
0.731
0.017
0.729
o
Males 3-11 yrs
Males >11-18 yrs
Females 3-11 yrs
Females>11-18 yrs
Group total
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19 13.7% 2.77 1.42 0.916
33 23.7% 2.36 1.38 0.206
51 36.7% 2.81 1.44 0.769
36 25.9% 2.66 1.35 0.709
139 100% 2.66 1.40 0.586
CHAPTER 5
RESULTS
PATIENTS AGED LESS THAN 3 YEARS OF AGE
The main diagnoses encountered in patients aged less than 3 years are presented in
Tables 5.1 and 5.2 and in Figures 5.1 to 5.12 on the following pages. For each
diagnostic group are graphed:
a) The number ofcases per age group by diagnostic group, and
b) The mean T4 per age group by diagnostic group.
Selection ofa control group
The Short Stature group (Figures 5.3a and 5.3b) was clearly an inappropriate control
group for patients aged less than 3 years, as there was an uneven distribution of
patients in this diagnostic group.
Conclusions
The type and frequency diagnoses encountered in patients aged less than 3 years was
different to those in the 3-11 years age group (Appendix F). Further work is required
to define the characteristics ofeach ofthe diagnostic groups for patients aged less
than 3 years. This would be feasible only after the identification of a suitable control
group for these patients.
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Table 5.1 Patients aged < 3 years: Number per age group by diagnostic group
Number per group
Age Group Failure to Jaundice Short Developmental Deafness Constipation Hydronephrosis Down's IDDM Slow Precocious Prematurity
Thrive Stature Delay Syndrome Growth Puberty
0-2wks 1 58 0 0 0 0 1 0 0 0 0 3
>2-4wks 11 50 0 2 0 3 1 1 0 0 0 3
>4-6wks 3 32 0 0 0 0 0 0 0 0 0 0
>6-8wks 14 16 1 1 0 2 3 0 0 0 0 0
>2-3mths 17 8 1 2 1 6 1 0 0 0 0 3
>3-4mths 8 2 0 1 0 1 1 0 0 0 0 0
>4-6mths 14 0 1 8 2 5 5 1 0 0 0 0
>6-9 mths 25 0 8 10 2 3 3 1 1 2 1 0
>9-12mths 29 0 17 20 2 1 3 2 1 1 2 1
>1-2yrs 56 1 51 29 17 10 3 7 6 4 5 0
>2-<3vrs 20 0 42 14 13 2 0 4 7 5 2 0
I
\0
\r)
I
Table 5.2 Patients aged < 3 years: Mean T4 per age group by diagnostic group
Mean T4 (nmol/L)
Age Group I Failure to Jaundice Short Developmental Deafness Constipation Hydronephrosis Down's IDDM Slow Precocious Prematurity
Thrive Stature Delay Syndrome Growth Puberty
0-2wks 289.0 167.3
- - -
. 253.0
- - - -
111.7
>2-4wks 174.9 157.1 . 160.0
-
180.7 215.0 98.0
- - -
155.3 I 1t'-->4-6wks 189.3 154.8 - - - - - . - - - - lr)I
>6-8wks 162.6 146.3 124.0 163.0
-
160.5 174.0
>2-3mths 161.5 162.3 102.0 157.5 191.0 172.7 204.0 .
- - -
225.7
>3-4mths 163.8 158.0
-
163.0
-
167.0 171.0
>4-6mths 132.4 - 147.0 159.8 196.5 156.6 154.6 166.0
>6-9 mths 133.6
-
139.8 144.1 112.5 111.3 155.0 210.0 128.0 129.0 136.0
>9-12mths 146.9
-
143.8 122.4 125.5 123.0 126.0 143.0 118.0 128.0 116.5 74.0
>1-2yrs 135.6 201.0 1365 129.7 135.1 130.3 122.7 139.7 119.2 126.0 164.2
>2-<3vrs 133.9 - 141.0 141.1 141.2 121.0 . 129.3 129.1 129.0 1635
Figure ,5.1a Failure to Thrive: Number per group Figure 5,11::> failure to Thrive: Mean T4 per group
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Figure 5,21::> Jaundice: Mean T4 per group
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Figure 5.5a Deafness, Number per group Figure 55b Deafn,,"", Mean T4 per group
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Figure 5.6a Constipation: Number per group Figure 5.6b Conlltipation: Mean T4 per group
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Figure 5.110 Pre<:odous Pubertyl Number per group Figure 5.111: Precocious Pubertyl Mean T4 per group
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CHAPTER 6
DISCUSSION
Description of the evidence
The source population was children living in N.S.W. aged 3-18 years ofage,
attending the RARC for thyroid function tests between 1980 and 1990 and recorded
in the Clinical Biochemistry Department log book. The initial inspection ofthe raw
data found infonnation on different diagnoses and almost complete thyroid function
test results for each entry were available.
The relationship between the thyroid function test results for each patient - thyroxine
(T4)' thyroid stimulating honnone (TSH) and triiodothyronine uptake, (T3U) and
presenting diagnosis was the basis ofour investigation using the fonnat ofan
epidemiological case-control study. This study type was chosen for analysis as the
patients were identified first on disease status and then on exposure (thyroid
function).
Hence the study factors for this study were the results of thyroid function tests for T4'
TSH and T3D, and the outcome factors were the various diagnostic groups
investigated. The research question was thus the relationship between thyroid
honnone levels and various diagnostic groups in children having thyroid function
tests at the RARC between 1980 and 1990.
The main results are shown below in Tables 6.1 and 6.2 in which are summarised the
general results per diagnostic group. The diagnostic groups are presented in two
separate categories by the initial findings ofa significantly high or low T4'
Table 6.1 shows the number ofpatients in each diagnostic group by thyroid function
test. Table 6.2 gives for each diagnostic group, median and quartile split odds ratios
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for T4. P-values calculated using the Wilcoxon Rank Sum Test are also included
here for each diagnostic group by thyroid function test. Highly significant p-values,
(p < 0.01) are shown in italics. These should be read in together with the odds ratios
given, to more accurately assess the possible relationship between T4 and diagnostic
state.
Table 6.1 Number of patients per diagnostic group by thyroid function test
Ref Group Number per group
T4 TSH T3U
1 SHORT STATURE (control) 1155 1117 1155
Significantly low T4
2B SELECTED DIABETES 462 443 462
lOA THALASSAEMIA 52 48 52
13A GROWTH HORMONE DEFICIENCY 50 47 49
4D ANOREXIA NERVOSA 17 14 17
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 20 18 20
11D ALL PSYCHOLOGICAL DISORDERS 18 10 18
4B CYSTIC FIBROSIS 32 28 32
Significantly high T4
3A OBESITY 174 139 174
18 DEAFNESS 25 4 25
4A FAILURE TO THRIVE 46 24 46
20B SLIPPED EPIPHYSES 9 6 9
14A TURNER'S SYNDROME 47 44 47
9A JUVENILE CHRONIC ARTHRITIS 8 5 8
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Table 6.2 Summary of results per diagnostic group
Odds Ratio on T4 p-vaIues*
Ref Group Median Quartile T4 TSH T3U
1 SHORT STATURE (control) 1.00 1.00
- - -
Significantly low T4
2B SELECTED DIABETES 1.46 2.34 0 0 0
lOA THALASSAEMIA 2.32 3.33 0.001 0.071 0.008
13A GROWTH HORMONE DEFICIENCY 2.40 2.96 0.002 0.786 0.683
40 ANOREXIA NERVOSA 3.09 4.79 0.003 0.407 0.778
15A ACUTE LYMPHOBLASTIC LEUKAEMIA 3.09 10.64 0.003 0.109 0.603
110 ALL PSYCHOLOGICAL DISORDERS 2.06 4.79 0.020 0.088 0.286
4B CYSTIC FIBROSIS 1.97 2.13 0.037 0.003 0.483
Significantly high T4
3A OBESITY 1.80 1.69 0 0.586 0
18 DEAFNESS 5.58 7.52 0 0.503 0.459
4A FAILURE TO THRIVE 2.22 3.13 0.001 0.055 0.975
20B SLIPPED EPIPHYSES 7.77
-
0.009 0.170 0.134
14A TURNER'S SYNDROME 2.07 2.00 0.011 0.002 0.841
9A JUVENILE CHRONIC ARTHRITIS 6.80
-
0.012 0.012 0.190
*Numbers in italics are p-values <0.01
Internal validity
Selection Bias
Selection bias can occur whenever the inclusion ofcases or controls into the study
depends in some way on the exposure of interest (Hennekens & Buring, 1987). It can
be a problem in case-control studies since the diseases have already occurred at the
time ofsubject selection and data on exposure is gathered retrospectively. In this
study the exposure is thyroid function and the disease is the list ofvarious diagnostic
groups. In an attempt to control for selection bias in this study, patients with known
thyroid disease were excluded. In a subset ofthe population, (letter IrA"), 8.9% were
excluded for this reason. The majority ofthe exclusions were to do with
inconsistencies in the data. A further analysis could record data on these exclusions
i.e. age, sex etc. These excluded groups could then be compared to the study
population to check whether they are significantly different and ifthey are, the
conclusions ofthe study be possibly re-defined.
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Measurement bias
Potential measurement bias ofthe outcome factor in this study include:
(i) The scope for error on the laboratory request form from which the data was
entered into the log book.
(ii) The diagnosis listed may be an assumption and possibly inaccurate, e.g. Anorexia
nervosa may have been diagnosed as simply just "thin", in which case it was entered
as such and not included as part ofthe anorexia nervosa diagnostic group.
(Hi) Scope for error in interpreting handwriting on both the request form and in the
log book. This ofcourse, applies to both non-numeric and numeric data. Generally,
though, the entries were fairly consistent. Mainly two members ofthe Clinical
Biochemistry Department, RARC, entered the thyroid function test requests and
subsequent results into the log book which was used as the basis for data entry.
When in doubt these small number ofentries were excluded so the bias was
decreased.
Data sorting, the exclusion ofduplicate entries and those ofunknown sex from the
analysis (as detailed in Chapter 2) also helped to control for measurement bias.
Measurement ofStudy Factor
Radioimmunoassay (RIA) techniques are used by the Clinical Biochemistry
Department at the RARC to test for T4 and TSH. T3U is a resin uptake test using
1-125 - labelled T3 and is reported as a ratio, therefore having no units. The N.UL. kit
was used to measure total T4. Total T4 is no longer routinely done, in favour of free
T4' The Coming Magic MAB kit is used to measure TSH. The total T4' TSH and
T3U tests all use N.UL. Thyrotrol as a control.
A varying mean T4 per year over 1980 to 1990 was noted in the total study
population (Figure 3.3b) and this is most likely due to an operator difference rather
than a change in the assay. The RARC assay method for T4 did not change over the
period 1980 to 1990. One person performed the assay during 1980 to 1989. From
1990 onwards, another person performed the assay. The control group was also
analysed in the same way as the total study population (Figure 3.4b) and the
variations were similar over time. It was concluded that this bias would then not
affect the case-control analysis.
Confounding
A confounder is any factor which affects exposure and disease simultaneously and if
not taken into consideration will lead to erroneous interpretation ofthe results.
Potential confounders identified in this study were thyroid disease, other diseases
which affect thyroid function, age, sex, puberty, year ofdiagnosis (see Measurement
Bias above) and some ofthe combined diagnoses. In this study, as exemplified
below, inclusion, exclusion, and stratification were strategies used to deal with
confounding (Figure 2.3).
Stratification was used to deal with age as this was identified as an interaction factor
- ie. a factor for which various subsets ofthe total populati0n are fundamentally
different from one another. In this case, the varying normal ranges for thyroxine in
patients aged less than and greater than 3 years ofage respectively indicate that the
two groups are metabolically different and hence not a homogeneous population.
Hence the total population was stratified into two categories: patients aged less than
3 years ofage and; patients aged 3 to18 years ofage.
Sex and puberty were considered confounders since a general review ofthe data
found that differences occurred in the overall data between age and sex with respect
to a possible link between T4 levels and age. This was especially important in pre-
and post- puberty groups with a decrease in T4 post-puberty. Females had a slightly
higher T4 than males in this population also. The data was then stratified by sex and
into pre- pubertal (3-11 years) and post-pubertal (>11-18 years) and each analysed
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separately for T4' TSH and T3U. It is interesting to note that in some cases, although
significance was achieved in the total group, this was not the case upon stratification.
This is most likely due to the small sample size in some ofthe stratified groups or
may be due to possible interaction effects. As these data are new and preliminary
analyses, further adjustment by conditionallogistical regression was considered
inappropriate, as it was considered important to analyse only crude, or stratified
effects.
Precision
With the number of statistical tests (p-values) calculated on the data as in this study,
it is likely that some ofthe results will show a falsely significant result, purely due to
chance (Rothman, 1986). Significance testing at the five percent level (p = 0.05)
means that there will be a 1 in 20 chance ofa false positive association. When odds
ratios were calculated, in some ofthe diagnostic groups, there were limited sample
sizes, especially in quartile splits, e.g. n=9 for Slipped Epiphyses and n=8 for
Juvenile Chronic Arthritis, and thus corresponding wide confidence intervals.
Therefore, chance variation in this study cannot be excluded as a possible
explanation ofthe results but looking at a significance level ofp < 0.01 and quartile
versus median splits (Table 6.2) confidence can be gained in the main results.
Methods to deal with the issues ofmultiple testing include redefining the level of
significance testing, either by changing the criterion to a more stringent value, such
as 1 per cent instead of 5 per cent, or by actually inflating the calculated p-values by
some factor that depends on the number ofcomparisons made (Rothman, 1986).
Temporal relationships
Case-control studies are commonly weak with respect to time relationships (Elwood,
1988). Due to the nature ofthe study, no data is available on the condition ofthe
patient before or after the diagnosis listed was made. Duplicate entries were
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excluded, 'keeping only the first chronological entry for each patient. A temporal
relationship ofthyroid function to disease can therefore not be assessed here.
Strength ofthe association
When assessing causality in an epidemiological study, the degree to which the risk of
thyroid function relating to diagnostic groups is indicated by the calculations ofodds
ratios. The numerically higher the odds ratio, the greater the probability of an
association being causaL In this study, the higher odds ratios tended to have wider
confidence intervals and smaller sample sizes (Tables 4.11 and 4.12)
A dose response relationship also increases the likelihood ofcausality as it gives an
indication ofthe consistency ofthe association in the data. When comparing median
and quartile odds ratios, the odds ratio increases from median to quartile split for all
except the obesity diagnostic group. This indicates a pr~bability that there is a causal
relationship between thyroid function tests and disease in all except the obesity
group.
External validity
These results can only be applied to the source population as hypotheses, as they are
based on descriptive data and give an indication ofa possible association between
thyroid function and the different diseases tested in the study population.
Comparison of the results with other evidence
In summary, most ofthe literature on the diagnostic states investigated, where
available, supports the various thyroid function test results for these groups. This is
discussed in more detail below by specific diagnostic group.
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Biological Causality
Diagnostic states can affect thyroid function in a variety ofdifferent ways. Generally,
conditions affecting the thyroid gland directly will be reflected in the results for T4'
Conditions which affect the hypothalamic-pituitary axis (HPA), or central
mechanism, will be reflected in the results for TSH. Conditions which affect protein-
binding mechanisms will be reflected in the results for T3U, in addition to T4. These
are discussed in more detail below within each diagnostic group.
In the various diagnostic states discussed below, the results of thyroid function
testing in the whole diagnostic group are summarised for each of T4' TSH and T3U
respectively:
H - significantly high result when compared to the control group
L - significantly low result when compared to the control group
N - not significant when compared to the control group
Selected Diabetes (L-L-H)
The diabetes diagnostic group gave the most striking results ofany other diagnostic
group giving a highly significant result throughout the three parameters tested. On
stratification, the only non-significant result was in the T4 result for patients aged 3-
11 years. T3U was significantly high when compared to the control group so this
indicates a reduced number ofbinding sites on plasma proteins (mainly thyroid
binding globulin or TBG) for T4' Reduced binding sites mean that the carrying
capacity ofTBG is less and so total T4 in plasma is lower. In a separate study, it was
also found that free T4 was low in diabetic children. (Coakley & Earl, 1994).
Although T4 is low and free T4 is probably low, this did not lead to a raised TSH
(which is the usual response). The usual HPA control mechanism then seems to be
impaired, indicating possible damage to the hypothalamus or the pituitary. Some
diabetics do go on to develop primary or secondary hypothyroidism, as the
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autoimmune process which affects the pancreas can also affect the thyroid or
pituitary glands in some patients.
From the literature, diabetes and thyroid function are linked at several levels. Kinetic
studies demonstrate a marked reduction in T4 to T3 conversion in poorly controlled
diabetics (pittman, et al 1979a, 1979b, cited in Middlesworth, 1986) and changes in
thyroid hormones levels are also seen in diabetics with ketoacidosis (parr, 1987).
Thalassaemia (L-N-H)
The results for this diagnostic group show a consistently low T4 across the total
group and upon stratification by sex and puberty. TSH was unaffected, suggesting
central receptors are not responding to the reduced T4 levels. This effect was
greatest in the 11-18 years age group. These results indicate a cumulative effect,
being greatest in the oldest age group, consistent with damage to the thyroid and/or
pituitary gland, as well as reduced or damaged plasma proteins. Free T4 may be
normal, even though total T4 is reduced. T3U was significantly higher in this
diagnostic group compared to the control group and this result indicates that binding
sites on TBG and other proteins are reduced. Although patients on known drug
therapy were excluded from this group, drugs used in the treatment ofthalassaemia
may displace T4 from the binding sites on TBG.
Thyroid dysfunction has been reported to occur frequently in thalassaemia major, but
its prevalence and severity varies in different groups (Landau et aI, 1993).
Thalassaemia is associated with increasing iron deposition in the endocrine cells and
generally with increased prevalence ofendocrinopathies. Progression is variable and
it may take years to progress from a normal state to hypothyroidism (Landau et aI,
1993). As the accumulation ofiron takes time to affect the thyroid gland, a marked
deficiency in thyroid function occurring in the older age group would be expected. It
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is thought that abnormal thyroid function with thalassaemia may be reversible in t~e .
early stages (Landau et ai, 1993).
Growth Hormone Deficiency (L-N-N)
In this study, GIlD patients showed a significantly lower T4 than the control group.
In females and in patients aged 3-11 years, T4 was not significantly different to the
control group. The normal T3U for all groups, indicated no abnormality with protein
binding ofT4. GIlD then, appears to affect thyroid function as a central effect. The
mechanism leading to low GH from the HPA may also result in a diminished
response to low T4' with TSH not being raised to correct the lower T4 level. The
idiopathic form ofGIlD may be divided into isolated GIlD and multiple pituitary
hormone deficiency, with possibly 50 per cent ofcases of idiopathic GIlD associated
with decreased secretion ofother pituitary hormones (Gunn, 1987).
Anorexia Nervosa (L-N-N)
A significantly low T4 was found in the anorexia nervosa diagnostic group (AX) in
this study with no difference in T3U or TSH when compared to the control group.
This effect was seen in females and also in the post-puberty group. As the sample
contained no males, the AX group was compared to Short Stature females and a
significantly low T4 was found (Table 4.13) as in the total group. Hence sex is not a
confounder in this diagnostic group. Anorexia nervosa is more commonly suspected
in females and this accounts for the sample profile ofthis group. It occurs most
commonly in post-pubertal females, so these are expected results.
As for GIlD above, the results for the AX group tend to indicate an altered central
mechanism (i.e. a lack ofTSH responsiveness to a low T4). In anorexia nervosa, a
mechanism for lowering T4 and hence energy expenditure and metabolic rate may
operate when energy reserves are reduced. This mechanism may operate at several
levels in T4 formation, including a lack ofTSH responsiveness to a low T4 and
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reduced T4 to T3 conversion in the tissues. Although a low TSH was not
demonstrated in AX compared to the control group, the sample size is relatively
small. Also, the RIA assay for TSH used in this study is not particularly sensitive in
detecting low TSH levels.
In a study ofonly ten patients with anorexia nervosa, Kiyohara et aI, (1989) also
found that basal T4' T3 and TSH were significantly lower before weight recovery in
patients with anorexia nervosa than they were in control subjects. This supports the
findings ofthe present study. After weight recovery, basal T4' and TSH levels were
unchanged and significantly lower in patients with the disorder. Basal T3
concentrations increased slightly after weight gain but still remained lower than the
control group.
In patients with anorexia nervosa, extremely low levels ofserum T3 are thought to be
the result of impaired peripheral conversion ofT4 to T3, associated with chronic
starvation, however, a dysfunctional HPA may also play a role (Kiyohara et ai,
1989). It has also been observed that serum TSH levels occasionally conflict with the
actual values ofcirculating thyroid hormones in patients with anorexia nervosa. This
also confirms the findings ofthe present study which did not find a significant
increase in TSH as a response to a low T4'
In a study by Bannai et al (1988), sixteen female patients with anorexia nervosa
during self-induced starvation displayed clinical findings suggesting hypothyroidism
in association with decreased serum total T4,and T3. This result suggests that the
peripheral metabolic state ofunderweight anorexia nervosa sufferers depends
considerably on the serum T3 concentration since, despite decreased total thyroid
hormone levels, the free T4 was normal in five ofthe sixteen cases examined,
(Kiyohara et ai, 1989).
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Acute Lymphoblastic Leukaemia (L-N-N)
A significantly lower T4 was noted in this diagnostic group (ALL), in females and
separately in pre- and post-puberty groups, but no significant difference was found
for T3U or TSH compared to the control group. It seems likely that some central
effect may be occurring here, reducing TSH responsiveness to a low T4. ALL
patients can have growth problems due to their treatment which may affect the
body's GH release mechanism. The same process could be affecting TSH
responsiveness, similar to the idiopathic form ofhypothyroidism. Although patients
on known drug therapy were excluded from this group, drugs used in the
chemotherapy ofALL patients do not appear to displace T4 from plasma proteins, as
T3U was unaffected.
Subtle primary hypothyroidism is relatively common in patients with acute
lymphoblastic leukaemia, particularly in those who have been treated with
craniospinal irradiation (pasqualini et aI, 1991). In the present study, patients who
were listed as having radiotherapy were excluded from the analysis. Ferster et al
(1992) measured parameters ofthyroid function in nine children during induction
therapy for ALL. During induction, total T4 significantly decreased, free T4' total T3
and TBG were decreased. During late intensification therapy, significant decreases in
T3 and TBG were observed, but there were no significant changes in T4 and free T4.
The authors concluded that during induction, the impairment ofthyroid function is
attributable to L-asparaginase, an enzyme, whereas during late intensification, low
T3 and low TBG is due to glucocorticoid administration.
Psychological Disorders (L-N-N)
The Psychological Disorders diagnostic group in this study is a heterogeneous
sample, with a number ofdisorders grouped to make a single diagnostic group.
These disorders were: Anxiety, Behaviour Disorder, Hyperactivity, Depression,
Aggression, Bipolar Active Disorder, Confusion and Psychotic illness.
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This group showed a significantly low T4 in males and in the pre-puberty group, but
no significant overall TSH and T3U effects, except for a significantly low TSH
finding in females. The findings are limited by a small sample size, (total n = 18). It
is unclear what relationship exists between psychological disorders and altered T4
metabolism but it should be noted that the AX group above, also a psychological
disorder, showed similar trends to the Psychological Disorders diagnostic .group.
A variety of severe psychiatric disturbances may be associated with transient
alterations in serum thyroid hormone levels, such as elevated serum total and free
T4, variable TSH and normal T3 concentrations (Spratt et aI, 1982). Nowotnyet al
(1990), investigated the correlation between pathological signs in thyroid disorders
and alterations ofperipheral thyroid hormones. They found that patients with latent
hyperthyroidism were more subject to somatic symptoms and affective complaints
than were those who had latent hypothyroidism. As compared with controls, there
were significant differences in exhaustion and pain in the limbs and heart and the
patients were more depressive, anxious, touchy and irritable; their personalities
showing a higher degree ofemotionallability, excitement and irritability.
Cystic Fibrosis (L-H-N)
In the Cystic Fibrosis diagnostic group (CF) a significantly low T4 and a significantly
high TSH were found. On stratification, a significantly high TSH was found only in
females. The males were not significant, most likely due to the reduction in sample
size upon stratification. TSH was also significant in the post-puberty group. T3U was
not significantly different from the c~ntrol group in any ofthe stratified groups. This
is clearly not a central effect because TSH is responding to the low T4 levels in the
blood. It is also not apparently a protein binding effect because ofthe normal T3U
result. It may also be that CF which affects all endocrine glands, is having an effect
upon either the thyroid gland or upon the turnover ofT4 in the tissues. However,
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histological abnonnalities ofthe thyroid gland have been reported in children with
cystic fibrosis (Braverman & Utiger, 1991).
Obesity (H-N-L)
In this study, the obesity diagnostic group (OW) overall was found to have a
significantly high T4' but TSH was not significantly different from the control group.
The result for T3U was also significantly lower when compared to the control group.
The T4 effect was lost on stratification by sex and only remained significant in the
pre-pubertal group. However, sub-stratification by sex and puberty still showed a
significantly raised T4 for both males and females in the 3-11 year age group.
This is very interesting because the findings for the OW group were opposite to the
AX group. However, the thyroid honnone biochemistry may be somewhat different
here as the OW group showed a significantly lower T3U level than the control group.
The lower T3U indicates more binding sites are available on plasma proteins and
hence T4 carrying capacity is increased.
In malnutrition, liver protein synthesis is reduced, so it may be that in well nourished
individuals protein synthesis, including TBG and other thyroid honnone binding
proteins, is increased. This would account for the decreased T3U level and increased
T4 levels in this group. T4 regulates the metabolism of lipids and clinically low T4
levels are often associated with high levels ofcholesterol and lipids in the blood.
Just as in anorexia nervosa, where there may be a mechanism limiting energy
consumption when energy reserves are low, in obesity, thyroid biochemistry may
also play a role in attempting to reduce excess energy reserves. A study by Chomard
et al (1985) found that thyroid function is disturbed in moderately obese patients,
mainly characterized by low serum total and free T3 concentrations which may be
due to a number offactors.
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Deqfness (H-N-N)
The deafness diagnostic group in this study showed a significantly high T4 but there
was no significant difference for T3U and TSH compared to the control group,
although sample size was a problem with testing for TSH (n = 4). The results ofthe
analysis were also consistent through stratification for sex. Upon stratification for
puberty, it was discovered that the Deafness diagnostic group contained data for
patients aged 3-11 years only. This sub-group was tested against the corresponding
control group (3-11 years) and a significantly high T4 was found (Table 4.13) as for
the total group. Therefore puberty does not appear to be a confounder in this group.
The occurrence ofcongenital deafness, mutism and goitre unassociated with
cretinism or mental retardation in euthyroid patients is known as Pendred's
Syndrome. It has been estimated that 4-10 % ofchildren with congenital deafness
suffer from this condition (Elamin, 1991). The perceptive hearing loss is considered
to be present at birth although it is frequently not recognized for several years. The
goitre becomes apparent in the pre-pubertal years. The thyroid defect has been
shown to lead to the underproduction of T4 and subsequent thyroid hyperplasia, and
has an equal incidence in both sexes which is unusual in thyroid disease.
However the present study did not fmd reduced T4 but rather raised T4' The reason
for this finding is uncertain but it may be related to a partial lack ofresponsiveness
in the tissues ofsome patients to thyroid hormones, leading both to hearing loss and
a disturbance in T4 regulation.
Jaffiol et al (1992) suggest that thyroid hormone resistance in children may affect
some or all tissues. The generalized resistance is an inherited disease which involves
goitre, increased free thyroid hormones with normal or elevated plasma TSH levels.
The hormone resistance effect is more in keeping with the findings ofthis study. As
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well as deafness, patients may present with men:tal retardation, short'stature and
delayed bone age.
Failure to Thrive (H-N-N)
The Failure to Thrive diagnostic group (FTT), showed a significantly high T4' but
did not show a significant result for T3U or TSH, when compared to the control
group. FTT showed varying significance upon stratification by puberty and sex. This
is not a protein binding effect since T3U was unaffected. It is difficult to ascertain
why T4 is significantly higher in the FTT group. However, the effect ofa raised T4
level is to increase basal metabolic rate (BMR) and energy consumption. Therefore,
depletion of energy reserves by a raised T4 may contribute to failure to thrive.
Slipped Epiphyses (H-N-N)
The Slipped Epiphyses diagnostic group (SE) showed a significantly high T4' but
there was no significant change in T3U or TSH, when compared to the control group.
There was varying significance upon stratification by puberty and sex. The small
sample size for this group (total n =9) must be taken into consideration in the
interpretation ofthese results.
It was initially unclear as to why there should be any relationship between a raised
T4 level and slipped epiphyses. However, a study by Brenkel et al (1989) suggests a
possible explanation. Fifteen patients with slipped capital femoral epiphyses were
investigated, and no difference in skeletal or sexual maturity between the study
groups, or any overt endocrine abnormality in the patients was found. However
almost halfthe patients with slipped epiphyses were over the 90th weight percentile,
suggesting that mechanical factors such as obesity are more important aetiologically
than endocrine abnormalities. In the present study, it was found that T4 was raised in
obesity. Ifpatients with slipped epiphyses are generally obese, then the SE group
could be demonstrating similar findings to the OW group.
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Turner's Syndrome (H-H-N)
In this study, the Turner's Syndrome (TS) diagnostic group showed a significant
raised T4, (especially post-puberty) and raised TSIt results (especially pre-puberty)
when compared to the whole control group (males and females). But T3U was not
significantly difterent from the control group in any ofthe stratified groups. Sex is a
confounder in this group as Turner's Syndrome occurs only in females. T4 in the TS
diagnostic group was not significantly different from T4 in control group females
(Table 4.13). Therefore, sex is a potential confounder in this diagnostic group,
although it must be noted that patients with Turner's Syndrome have only one X
chromosome, so in a chromosomal sense, are not truly female.
Juvenile Chronic Arthritis (H-L-N)
In this study, the Juvenile Chronic Arthritis diagnostic group (JCA) showed a
significantly high T4 in females and in the pre-puberty groups. A significantly low
TSH was noted only in the whole group, compared to the control group. T3U was not
significantly different to the control group in any ofthe stratified groups tested.
These results should be interpreted with caution as the total group was comprised of
only eight patients and this small sample size will affect the results. This is
evidenced by the large confidence interval given with the median odds ratio result.
Although the OR is 6.80, it is not significant as the confidence interval range
includes the number 1. The quartile split could not be calculated. The results indicate
central mechanisms are operating normally with TSH levels reduced in response to a
raised T4.
It appears likely that drugs used in therapy for juvenile chronic arthritis may alter T4
metabolism. Herrmann, et at (1989) investigating the pathogenesis and clinical
relevance ofdecreases ofT3 level in 63 patients with rheumatoid arthritis (59 of63)
and systemic lupus erythematosus (4 of63) and found decreases and low normal
values for the total T3 in 33 ofthe 63 patients who were included in the study. The
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remaining 30 patients exhibited a distinct reduction oftotal T3 and free T3, low
normal total T4' a moderate decrease ofthe basal and stimulated TSH, and only a
very small restriction ofthe binding capacity ofTBG. It is known that anti-rheumatic
drugs, in particular glucocorticoids, may induce such a response (Herrmann et aI,
1989). Although patients on known drug therapy in this study were excluded from
the analysis, most children with juvenile chronic arthritis would have been receiving
drug therapy, even though it was not stated in the clinical notes.
Conclusions
In summary, it appears that ofthe diagnostic groups in the significantly low
thyroxine category, Selected Diabetes is showing protein-binding as well as central
or HPA effects; Thalassaemia is showing protein-binding effects; Growth Hormone
Deficiency, Anorexia Nervosa, Acute Lymphoblastic Leukaemia and the
Psychological Disorders diagnostic groups are showing direct thyroid gland effects;
and Cystic Fibrosis is showing HPA effects.
Ofthe diagnostic groups in the significantly high thyroxine category, Obesity is
showing protein-binding effects; Deafness, Failure to Thrive and Slipped Epiphyses
are showing direct thyroid gland effects; Turner's Syndrome and Juvenile Chronic
Arthritis are showing a HPA effects.
Many ofthese fmdings are novel and are pointers to new directions for future
research in the relationship between thyroid hormone biochemistry and disease
states, particularly with regard to Obesity, Anorexia Nervosa, Diabetes, Failure to
Thrive and Cystic Fibrosis.
Having defined diagnostic groups where subtle differences occur in thyroxine levels
compared to the control group, some limitations have been identified in the study.
Patients with abnormal thyroid function tests have been excluded via primary and
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secondary criteria. In future investigations, it is suggested that these excluded groups
be included separately in the analysis and compared to the control group.
In inferring causality, it can be said that this study had good precision. Aspects of
validity, i.e. confounding and measurement bias were well accounted for in this
study, and it is thought that selection bias did not adversely affect the findings ofthis
study. The degree ofassociation in each case was substantial but not large (quartile
odds ratio range 1.69 to 10.64) and most ofthese associations were supported by a
dose response relationship in median and quartile split comparisons.
Care must be taken in the interpretation ofthese results. There are some strong
biological hypotheses to support these findings. However, in a study ofthis type, a
temporal relationship between exposure (thyroid function) and disease (diagnostic
groups) cannot be defined. Further investigation would be required to confirm these
fmdings. This would be best achieved by measuring free T4 and TSH levels using the
more sensitive and specific monoclonal antibody method currently available, on a
larger sample size for the groups ofinterest.
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THIS APPLICATION MUST BE TYPEWRITTEN
If this project includes any information ofa commercial orpatentable nature,
this information shouldbe sent separately andmarl<ed ·Confidential",
1. Project Title (~ Trtle)
AN INVESTIGATION.OF THYROXINE LEVELS IN A POPULATION OF SYDNEY CHILDREN
INCLUDING NORMAL VERSUS DIAGNOSES OF DIABETES, LEUKAEMIA, OBESITY,
ANOREXIA, LETHARGY AND TALLNESS.
.... '
2. Name(s) Title(s) Department I Building Code I Location and Telephone Number(s) of Chief, Associate and Co-
Investigators
1. Anna Agnos, Student - Master ofCommunity Health, Cumberland College ofHeaIth Sciences,
University ofSydney. Telephone: 922 7688.
2. Or. Kaye Brock, Senior Lecturer, CumberIand College ofHealth Sciences, University ofSydney,
East Street, Lidcombe NSW 2141. Telephone: 6466124.
3. Or. John Earl, Developmental Biochemist, The Children's Hospital, Pyrmont Bridge Road,
Camperdown NSW 2050. Telephone: 692 6280.
4. Or. John CoakIey, Head ofClinical Biochemistry, The Children's Hospital, Pyrmont Bridge Road,
Camperdown NSW 2050. Telephone: 692 6633.
3. (A) Proposed Date of Commencement of Project. You are reminded that Protocols should not commence
without prior written approval from the Human Ethics Committee.
November 1993
(B) Proposed duration of project
12 months
4. Where will the procedures involving humans be undertaken? .
No contact with humans win be made as the project involves a detailed data analysis only. This analysis
will be undertaken at The Children's HospitalCamperdown.
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:---"7-:';,.-,...--~:""-_":'::-~---------,---......,..--- HUMaN ETHical PROTOCOl--':""":
"
please Note: Thatthe order ofthe -Yes- a~d -No- boxes are reversed in Questions: 10.3, 13, 17, 18,19
(~art 2) and, 24. ',,' " , " ' ,.
The nature of this Research is best described as
Therapeutic Research in which the experimental Intervention .ill expected to benefit the subject directly
Therapeutic Research in which the experimental intervention is.llQ1 expected to benefit the subject directly
Clinical Trial. (Please indicate name of-pharmacologist involved in preparing the protocol below
[) 0
No Yes I
~ 0
No Yes
fi) 0
No Yes -.
Human Physiology Research [) 0
No Yes
Behavioural Research [) 0
No Yes
Questionnaire only (Go directly to Question 14) [) 0
No Yes
Others (Please indicate nature of Research immediately below) 0 [)
No Yes
Psychopathology [) 0
No Yes
Qualitative Evaluation Research 0 0
No Yes
Biomechanical Research !Kl 0
No Yes
Epidemiological analysis of previously collected data,
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6. Is there a requirement for violation of the integument of subjects (including drug absorption,
needle stick, rectal probes, pharyngeal foreign bodies)?
o
No
o
Yes
If you answered YES please state in what way the integument is planned to be violated, all the risks involved,
and if possible with ymat incidence you expect these risks. (These risks must be included on the consent form).
,
7. Is placental tissue used?
8. Is tissue planned for culture?
9. Are human embryos involved in the Research?,
10. Is somatic gene cell therapy used?
10.1 Is the disease being treated due to a defect in more than a single pair of genes?
10.2 Does the disease have an effective alternate treatment?
10.3 Does the diseases being treated have measurable index of response to therapy?
11. Will radioactive substances be used?
12. Will the use of recombinant, DNA techniques, toxins, mutagens, teratogens or carcinogens
be involved?
13. If a threat to health occurs to a subject are there sufficent facilities or contingencies
available to deal with such problems?
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0-0
No Yes
~ 0
No Yes
[) 0
No Yes
0 0
No Yes
fB] 0
No Yes
fKlD
No Yes
0 [)
Yes No
0 0
No Yes
lKlD
No Yes
NJA 0 0
Yes No
---:::-:•• :::-:.'.!.-;'.,:-:-:.:..'+:..,~,"';':';::':'~:;". .....,:,~""':''';':''.;.,.''::':';'l,,-,'~ ---,- HUMAN ETHICAL PAOTOCOl-~.,..
14. ,Are the subjects:-
14.1 Children?
14.2 Elderly person~'who may have legal capacity, but may be in a position where they are
unable to give a free or comprehending consent?
14.3 Mentally ill?
14.4 Unconscious or critically ill patients?
14.5 Wards of state?
14.6 Prisoners?
14.7 Members of the armed services?
14.8 In a doctor-patient relationship?
14.9 In a health giver/health receiver (with respect to the researcher Isubject) relationship?
14.10 In a teacher-student relationship
14.11 In an employer - employee relationship?
14.12 General public
14.13 Not Applicable
If you answered Yes, to 14.13 please give reas~ms
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No Yes
[I 0
No Yes
[I 0
No Yes
[I 0
No Yes
(g)' D
No Yes
!El D
No Yes
fIl 0
No Yes
[ID
No Yes
[) 0
No Yes
~D
No Yes
fR) 0
No Yes
,0 fEl
No Yes
NIJ\ 0 0
No Yes
.-
----:-:---7---:"-:'.:-7...~<--:-~~----------------~HUMAN ~ICAL PROTOCOl:~---
15. Is there a requirement for a department, school, faculty, or organisation to disclose
information of personal details without written consent from the subject?
If you answered yES please state what these details are and why written consents not possible?
.'
This project involves data analysis oflaboratory tests collected over a number ofyears. All patient names will be
assigned a unique code and these codes used in the analysis. Medical Records will not be accessed at any time.
16. Is there any possibility that personal details of a subject could be revealed to persons
not directly connected with this project?
17. Will a written consent be obtained?
If you answered NO please give reasons (a consent form may be unnecessary for a questionnaire)
Please see Question 15.
18. Will a Subject Information Sheet be supplied (likely to be unnecessary for a questionnaire)?
If you answered NO please give reasons.
Not required - please see Question 15.
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00
No Yes
00
No Yes
0.0
Yes No
00
Yes No
la the research' targeting an Ethnic minority or.Community group?
If you answered YES what group are you targeting?
9.
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o D'...;:"'4~:: ..;,
No Y "":;";: ""~,,:'}~as .~ ',~ t:~/J, I .,~;
If you answered YES has this been done in consultation with a representative of this group? N/A 0 0
Yes No
If you answered YES who have you consulted, and how do they represent this group?
Is there psychological or physical stress placed on the subjects? 00
If you answered YES, please state what this might be.
No Yes
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21. Is compensation planned for the subjects?
If you answered YES, is the compensation sufficient to act as an inducement to enrol?
If you answered YES, what is the amount and the justif.ication for this?
22. Do the researchers expect to obtain any financial benefit from conducting this project?
(NB. this does not include grants)
If you answered YES, please explain.
23. Does recruitment of participants involve a direct personal approach from the researcher to
the potential subject?
00
No Yes
NJA 0 0
No Yes
00
No Yes
[ID
No Yes
If you answered YES, is there any researcher or peer group pressure that might influence the
potential s~bject to enrol.
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_--=-- ....:.'.:...._'...:......:._....:..:~_.'._ ...::."'-:...:.,:....:...•_.. --:- HUMRN ETHICRl PROTOCOL._~ '_ ."
·if fo'u answered YES, please explain reasons.
Are the subjects~ to withdmw from participating in the project at any time (this must be
stated on the consent form or questionnaire)?
(ie. subjects can withdraw at any time and are aware of this option)
If you answered NO, please state reasons.
Please see Question 15.
5. Has this project been submitted to any other Ethics Committee?
If you answered YES, please state which Committee?
6. Has approval for this project been granted from any other Ethics Committee?
If you answered YES, please attach a copy of the approval.
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Yes No
00
No Yes
00
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27. Brief outline proposed project and Its Importance (please do not exceed space prOVided as It will not be read)
(References to be included separately)
The thyroid ,ho~ones, and especially thyroxine (T4), have three principal effects on'
the body: (a),r~gulation of metabolism, (b) regulation of growth and development,
and (c) regulation of the activity of the nervous system (1). With respect to the
regulation of metabolism, the thyroid hormones stimulate virtually all aspects of
carbohydrate and lipid metabolism in most cells of the body and increase the rate of
protein synthesis (I).The thyroid hormones also help to regulate tissue growth and
development, especially in children (1).
Over 10 years data, on thyroid function tests have been collected by laboratory staff
at the Children's Hospital, Camperdown in Sydney. Over this period, staff have
noticed a possible trend in this data with respect to certain diseases.
The aim of this project is to review thyroxine and possibly free thyroxine index (FT!)
and thyroid stimulating hormone (rSH) with sex and age in a number of different
"normal" (control) and disease (case) groups via an extensive computer analysis of
the data available. Variations in T4 within the normal range will be the focus of the
research.
In the interests of maintaining patient anonymity, all patient data will be numerically
coded for use during the analysis and in any subsequent publications. No use of
Medical Records will be required at any stage of the project.
Control groups will be patients with the following diagnoses:
Short Stature for Investigation. Apart from the occasional case of hypo thyroidism
which can be eliminated by abnormal T4 or TSH results, this is a relatively normal
group.
Cystic Fibrosis. Growth problems are due to fat malabsorption rather than due to
hormonal changes so this is group will also be used as a control group.
Cases include those with the following diagnoses:
Insulin-dependent Diabetes Mellitus. This typ~ of diabetes (Type I), generally
develops during childhood, the peak incidence being at puberty (2). Insulin secretion
by the pancreas is either substantially reduced or non-existent. As a result, changes in
metabolism occur which lead to a varietY of symptoms and can be fatal if left
untreated (2). It is thought that this group may have slightly lower T4 levels than
normals.
Acute Lymphoblasic Leukaemia. This type of leukaemia is a malignant disorder of
certain bone marrow cells of which the cause is unknown (2). Typically the onset is
acute or subacute in a previously healthy child, or less commonly, in an adult.
Clinical symptoms include weakness, fatigue, infection and bleeding (2). Leukaemia
patients after their chemotherapy and radiotherapy are, tested to see if they have
- 9-
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27. (continued)
damage to their .pituitary gland, which regulates many ofthe body's hormones.
Obesity/Anorexia/Lethargy/Tallness. It is not known whether minor differences in
thyroid hormones play a role in these conditions.
Therefore it is anticipated that a comprehensive analysis of the data available will
show the expected trends and ultimately lead to a better understanding of these
important childhood diseases.
-10 -
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No Yes
28. ~re there any further ethical considerations that you may wish to raise?
__________________________ HUMAN ETHICAL PROTOCOl---
Ofll
If you answered Yes, pleas~ state what these considerations are.
As the raw data contains the names of patients and
laboratory test results, each patient will be assigned a
un~que number to be used in subsequent data analysis.
Once coded, the names and corresponding numbers will be
destroyed, in the interests of preserving patient
anonymity. Medical Records will not be accessed at any
time.
29. Checklist
The following documents are attached (Please tick where applicable).
o Copy 0f Consent Form
o Copy of explanatory material for participants (subject information sheet)
o Evidence of permi~.sjon to conduct research in locations not associated with the University of Sydney.
o Evidence of approval by another ethics committee
o References relevant to Question 27.
o Copy of Questionnaire (s) to be used in the research
o Copy of the statement from Medical/paramedical practitioner accepting responsibility for procedures.
o Copy of any ethical approval form requiring signature (eg. NH&MRC attachment I Certificate)
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. . .
Ifapproval is granted for this research, it will be done so, on the understanding that the enclosed
information is a true record of my research.
,
..
". .:..
Signature of Chief Investigator or Supervisor
Name:
. i< ·6Roelc.
.............................................................................................................
. (please print)
Signat~re .......••.•..•.............!.<r.:.~ 1..?f.~~~:.I:::. ~ .
Date 6!1()19~ .............................................................................................................
Signature of Associate Investirtor (;J. () .
oL,-~ [CJ
Date •::::::::::.::~:;:E:~J;:;.::-':::-'.-'..::::::::::~::::::-.-.: -...:.:::~-.:.: ..
Signature of Student
Date
IlNNt:I IIGNoS -~.r---'
......................................................····:···U·································
.........~f./(9j9.3. .
Signature of Dean of Faculty OR Head of Department OR Head of School
Name: .......................... u •••••• .
Signature
"' !"1pfease print)
.............C:!.\.\:.~~ ..>.~ .
Date
c '\ . -::?~ \ C> 0 ~
................................. . .\ -\- .
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APPENDIXB
DIAGNOSIS CODES
Code Meaning/Alternative
A ALPHA-l AT DEFICIENT
AA ASPHYXIA/PERINATAL ASPHYXIA
AB ABAGELLES SYNDROME
ABA ADVANCED BONE AGE
ABN ABNORMAL/ABNORMALITY
ABP ABDOMINAL PAIN/ABDOMINAL DISCOMFORT OR BLOATING
AC ACROMEGALY
ACS ACIDOSIS
ACY ANOVULATORY CYCLES
AD ADDISONS DISEASE
ADR HYPOADRENALISM
AF ATRIAL FIBRILLATION
AG AGGRESSION / EMOTIONAL LABILITY
AGD ARGINASE DEFICIENCY
AI ADRENAL INSUFFICIENCY
AIDS ACQUIRED IMMUNE DEFICIENCY SYNDROME
ALB LOW ALBUMIN
ALC ALCOHOL ABUSE
ALL ACUTE LYMPHOBLASTIC LEUKAEMIA
AM AMENORRHOEA
AM! PRIMARY AMENORRHOEA
AM2 SECONDARY AMENORRHOEA
AML ACUTE MYELOBLASTIC LEUKAEMIA
AN ANAEMIA - All types except Sickle Cell Anaemia
ANX ANXIETY/AGITATION
AP ALOPECIA (AREATO)/HAIR LOSS/FALLING HAIR
APN APNOEA
ARR CARDIAC ARRHYTHMIA/MURMUR
ART ARTHRITIS/ARTHRALGIA/RHEUMATOID ARTHRITIS
AS ASTHMA
AT ATAXIA
AX ANOREXIA NERVOSA/DEPRESSED APPETITE
AY ARTHROGRYPOSIS
B BLACKOUTS
B12 VITAMIN B12 DEFICIENCY
BA BILIARY ATRESIA
BAD BIPOLAR ACTIVE DISORDER
BC BRADYCARDIA
BCH BONE CHANGES/SKELETAL DYSPLASIA
BD BEHAVIOURAL DISORDER/PROBLEM
BE BONEPAIN
BH BILATERAL HARRISON-SULKA DISEASE
BI CONJUGATED BILIRUBIN
BL BLIND/VISUAL DIFFICULTY
BD BILATERAL PTOSIS
BR BRONCHITIS/BRONCHIOLmS
BS SHORT BOWEL SYNDROME
-103 -
BU
C
CA
CAH
CAN
CAR
CAT
CB
CD
CE
CF
CH
CHD
Cl
CJ
CM
CN
CO
COF
COH
COHD
CON
CQ
CR
CRF
CS
CT
CU
CY
D
DBA
DBD
DD
DEAF
DEF
DEP
DFE
DGD
DH
DJ
DL
DM
DMY
DO
DP
DR
DS
DT
DU
DUS
DV
DW
BULIMIA NERVOSA
CARDIAC DISEASE
(MULTIPLE) CONGENITAL ABNORMALITY/MIDLINE DEFECTS
CONGENITAL ADRENAL HYPERPLASIA
CANDIDIDIASIS
CAROTENAEMIA
CATARACTS
DECARBOXYLASE DEFICIENCY
COELIAC DISEASE/"COELIAC"
CHROMOSOME ABNORMALITY
CYSTIC FIBROSIS
CHOLESTASIS
CONGENITAL HEART DISEASE
COLD INTOLERANCE/SENSITIVITY
CHOLESTATIC JAUNDICE
CARDIOMYOPATHY
CYSTINOSIS
CRYPTORCillDISM/UNDECENDED TESTES
CONFUSION/DELIRIUM
COHENSSYNDROME
CORONARY HEART DISEASE
CONSTIPATION/INTESTINAL OBSTRUCTION
CHONDRODYSPLASIA
CIRRHOSIS
CHRONIC RENAL FAILURE
CUSHINGS SYNDROME/"CUSHINGOID"
COARCTATION
CYSTINURIA
CYST/ ARACHNOID CYST/BRACHIAL CYST
DIABETES
DELAYED OR RETARDED BONE/OSSEOUS AGE
DIAMOND BLACKFAN DEFICIENCY
DEVELOPMENTAL DELAY/SLOW/MOTOR DELAY/DELAYED PROGRESS
DEAFNESS/(CONGENITAL) HEARING LOSS OR DIFFICULTY
"DEFICIENCY"
DEPRESSION
DELAYED/ ABSENT FEMORAL EPIPHYSES
DEGENERATIVE DISEASE/NEURODEGENERATIVE DISEASE
DRY HAIR
DIABETES INSIPIDUS/NEPHROGENIC DIABETES
DENTmON LOSS
DIABETES MELLITUS
DERMATOMYOSmS
DRY MOUTH
DYSPEPSIA
DIARRHOEA
DOWN'S SYNDROME/TRISOMY 21
DYSTONIA
DUODENAL ULCER
DUMPING SYNDROME
DEPRIVATION
DWARFISM
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DY
DYS
DZ
EAT
EB
EC
ED
EN
EO
ER
ES
F
FAL
FDS
FH
FL
FSHD
FIT
FU
FV
GAIT
GAL
GAST
GAU
GD
GDIS
GEN
GHD
GIG
GM
GP
GR
GRE
GRS
GS
H
HA
HB
HCAL
HCH
HCN
HE
HEP
HEPB
HF
HG
HGO
HH
HI
HIN
HIP
HI<
DYSMATURE
DYSMORPIDC/COARSE FEATURES/"DISMORPIDC"
DIZZINESS
EATING DISORDER/POOR FEEDING/FOOD INTOLERANCE
EBSTEINS ANOMALY
ECZEMA
(POLY)EPIPHYSEAL DYSPLASIA
ENEURESIS
EXOPTHALMOS/PROMINENT EYES
ENCOPORESIS
EPISTAXIS
FEMALE
TERATOLOGY OF FALLOTS/"FALLOTS"
FOETAL DILANTIN SYNDROME
FAMILY IDSTORY
FLOPPY BABY/FLOPPINESS
FOLLICLE STIMULATING HORMONE DYSTROPHY
FAILURE TO THRIVE/POOR WEIGHT GAIN
FLUSHING
FEVER
GAIT DISTURBANCE
GALACTOSAEMIA
GASTROSCHESIS
GAUCHERS DISEASE
GROwrn DELAY, RETARDATION, FAILURE
GROwrn DISORDER
AMBIGUOUS GENITATLIA
GROwrn HORMONE DEFICIENCY
GIGANTISM
GYNAECOMASTIA
G-6-PD DEFICIENCY
GALACTORRHOEA
GREY HAIR/PREMATURE GREYING OF HAIR
GOULD REGRESSION SYNDROME
GROWTH SPURT/RECENT GROWTH SPURT
HERNIA
HYPERACTIVE/OVERACTIVE JITTERY
CONGENITAL HYPERBILIRUBINAEMIA
HYPOCALCAEMIA
HYPERCHOLESTEROLAEMIA
HOMOCYSTINURIA
HAEMOPIDLIA
HEPATITIS/CHRONIC ACTIVE HEPAmIS
HEPATITISB
HYPOREFLEXIA
HYPOGLYCAEMIA
HYPOGONADISM/GONADAL DYSGENESIS OR FAILURE
HEMIHYPERTROPHY
IDRSUTISM
HYPERINSULISM
IDRSCHSPRUNGS DISEASE
HYPOPLASTIC KIDNEY
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HLD
HND
HN
HO
HOV
HPAL
HPHR
HR
HS
HSM
HT
HU
HUS
HV
HW
HYN
HYP
lA
IBS
IC
ID
IDDM
IF
IG
IH
IHG
IM
INF
10
IP
IR
IS
J
JCA
JRA
LA
LAC
LAF
LET
LF
LP
LU
M
MA
MAC
MAL
MAP
MAR
MAS
MB
MD
MEN
HYPERLIPIDAEMIA
HYPERNATRAEMIC DEHYDRATION
HYPOTONIA
(POSTURAL) HYPOTENSION/LOW BLOOD PRESSURE
HYPOVENTILATION
HYPOALUMINAEMIA
HYPOPHOSPHATAEMIC RICKETS
HYPERTRICHOSIS
HEADACHES
HEPATOSPLENOMEGALY
HYPERTENSION
HURLERS DISEASE
HAEMOLYTIC URAEMIC SYNDROME
HOARSE/HUSKY VOICE
HISTIOCYTOSIS/HISTIOCYTOSIS X
HYDRONEPHROSIS
HYPOTHERMIA
INCREASED APPETITE
IRRITABLE BOWEL DISEASE/ABNORMAL BOWEL MOTILITY
ICTARUS
AUTOIMMUNE DISORDER
INSULIN DEPENDENT DIABETES MELLITUS
IDDM NEPHROPATHY
INCONTINENTIA PIGMENTIA
HEAT INTOLERANCE
INCREASED HAIR GROWTH
INFECTIOUS MONONUCLEOSIS
VIRAL OR OTHER "INFECTION" (UNSPECIFIED)
IRON OVERLOAD
IRREGULAR PERIODS/MENSTRUAL IRREGULARITY
IRRITABILITY
INSOMNIA
JAUNDICE
JUVENILE CHRONIC ARTHRITIS
JUVENILE RHEUMATOID ARTHRITIS
LYMPHADENOPATHY
LACTIC ACIDOSIS
LARGE OR WIDE ANTERIOR FONTANELLE/DELAYED CLOSURE OF FONTANEL
LETHARGY/TIREDNESS/FATIGUE/SLEEPINESS
LIVER FAILURE
LIMB PAIN/LEG PAIN
LUNG DISEASE
MALE
MASTOPATHY
MACROCEPHALY/MEGALOCEPHALY/LARGE HEAD
MALAISE
MACROPHALLUS
MARFANS SYNDROME
McCUNE ALBRIGHES SYNDROME
MALABSORPTION/LIPID OR STORAGE DISORDER
MATURATION DELAY
MENORRHAGIA
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MF MULTI FOCAL THROMBI
MG MYASTHENIA GRAVIS
MGt MACROGLOSSIA/LARGE OR PROMINENT TONGUE
MIO MICROPTHALMOS
MIP MICROPHALLUS
MMA METHYL MALONIC ACIDOSIS
MMC MYELOMENINGOCOELE
MN MYOTONIA
MNT MALNUTRITION/INADEQUATE DIET
MO MALROTATION
MOD MATURITY ONSET DIABETES
MP METABOLIC PROBLEM
MQ MOOD DISTURBANCE
MT METAPHYSICAL DISEASE
MU MUSCLE PAIN
MW MUSCLE WASTING
MX PERSISTENT MOTTLING
MYO MYOPATHY
N NEPHROSIS/CONGENITAL NEPHROSIS
NA NAUSEA
NAT HYPONATRAEMIA
NO NOONANS SYNDROME/DISEASE
NH NEONATALHEPATITIS
NIDDM NON-INSULIN DEPENDENT DIABETES MELLITUS
NL NARCOLEPSY
NP NEUTROPAENIA
NYS NYSTAGMUS
OC OVARIAN/CERVICAL CYST
OE OEDEMA
OFS OPITZ FRIAR SYNDROME
OH OPTIC (NERVE) HYPOPLASIA/OPTIC ATROPHY
OM OLIGOMENORRHOEA
OP OSTEOPOROSIS/JUVENILE OSTEOPOROSIS
OVE OVARIAN ENLARGEMENT
OW OVERWEIGHT/OBESE/PLUMP/INCREASED FAT
P PALLOR/PALE
PA PAPILLmS
PALP PALPITATIONS
PAT GROWTHPATTERN
PBS PRUNE BELLY SYNDROME
PC PERICARDmS
PO PUBERTAL DELAY/PUBARCHE
POA PATIENT DUCTUS ARTERIOSIS
PDY POLYDYPSIA/INCREASED DRINKING
PE POLYENDOCRINOPATHY
PF PUFFY FACE/EYES
PH PREMATURE TITRACHE
PI PSYCHOTIC ILLNESS/PSYCHOSIS
PLE PROTEIN LOSING ENTEROPATHY
PM POLYMYOSmS/MYosms
PMS PREMENSTRUAL SYNDROME
PN POLIOMYELITIS/"POLIO"
PNE
pp
PREM
PS
PT
PU
PUO
PV
PWG
PWS
PY
R
RAY
RC
RCA
RO
RE
RG
RN
RP
RSS
RT
RTA
S
SA
SAH
SAP
SB
SC
SCH
SO
SE
SG
SGA
SI
SIADH
SJS
SK
SLE
SLOW
SO
SPD
SPF
SQ
SS
SSG
ST
SVT
SYN
SW
T3U
T4
PNEUMONIA
PRECOCIOUS PUBERTY OR DEVELOPMENT
PREMATURE
PERTUSSIS
PROPTOSIS
POLYURIA
PYREXIA OF UNKNOWN ORIGIN
PESCAVUS
POOR/SLOW WEIGHT GAIN
PRADER-WILLI SYNDROME
PYREXIA
RUBELLA/CONGENITAL RUBELLA
RAYNAUDS PHENOMENON
RENAL CALCULI
RED CELL APLASIA
RENAL DISEASE/DYSPLASIA
RESPIRATORY DISTRESS
RAPID/ACCELERATED GROWTH
RINGING IN HEAD
RECTAL PROLAPSE
RUSSELL SILVER SYNDROME
RETINOSIS PIGMENTOSA
RENAL TUBULAR ACIDOSIS
SWEATY/ MOIST PALMS/NIGHT SWEATS
SICKLE CELL ANAEMIA
SUBARACHNOID HAEMORRHAGE
(INCREASED) SERUM ALKALINE PHOSPHATASE
SPINA BIFIDA
SCLEROSIS
SCHWACHMAN'S DISEASE
SLOW DENTITION/DENTITION DELAY
SLIPPED EPIPHYSES
SLOW OR POOR GROWTH/DECREASED GROWTH RATE
SMALL FOR GESTATIONAL AGE
STILLS DISEASE
SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE
STEVENJOHNSON SYNDROME
SKIN DISORDER/SPIDER NAEVUS
SYSTEMIC LUPUS ERYTHEMATOSISI"LUPUS"
INACTIVE
SOTOS SYNDROME
SPEECH DELAY
SMALL PITUITARY FOSSA
SQUINT
SHORT STATURE/SMALL
SHORT SLOW GROWTH/SMALL SLOW GROWTH
SPLENOCYTOSIS
SUPRAVENTRICULAR TACHYCARDIA
SYNCOPE/RECURRENT SYNCOPE
SLOW TO WALK/DELAYED WALKING
TRIIOOOTHYRONINE UPTAKE
THYROXINE
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TALL TALL STATURE/TALLNESS
TC TACCHYCARDIA/TACCHYARRYTHMIA
THAL THALASSAEMIA
TL TENDER OVER
TN 1HIN/SKINNY/UNDERWEIGHT/SLENDER/LOW WEIGHT
TPN TOTAL PARENTERAL NUTRITION
TR TREMOR
T8 TURNERS SYNDROME
T8H THYROID STIMULATING HORMONE
U SEX UNSPECIFIED
UC ULCERATIVE COLms
UH UMBILICAL HERNIA
UI URINARY INCONTINENCE
URTI UPPER RESPIRATORY TRACT INFECTION
UTI URINARY TRACT INFECTION
V VITILIGO
VB VAGINAL BLEEDING/SPOTTING
VC VOCAL CHORD PARALYSIS
VO VOMmNG
VR VON RICK DISEASE
VSD VENTRICULAR SEPTAL DEFECT
VUR VESICO-URETERIC REFLUX/"REFLUX"
W WASTING/GENERALISED WASTING
WO WILLIAMS DISEASE
WG WEIGHT GAIN
WK WEAKNESS/POOR MUSCLE TONE
WL WEIGHT LOSS/DECREASED WEIGHT VELOCITY
WP WEIGHT PROBLEM
APPENDIXC
COMBINED DIAGNOSES CONVERSIONS"
Patients aged 3 - 18 years
A/LF
ALL/COF
ALL/OW
ALL/SG
ALL/SS
AML/SS
AML/WG
AN/SLOW
AN/SS
AN/WL
ANX/TR
ARR/SLOW
ART/FV
AS/TC
AX/HN
BP/SS
C/FH
CAR/PP
CAR/SG
CAR/SS
CAR/WG
CD/OW
CD/WL
CF/IDDM
CF/MNT
CF/SS
CHD/HF
CHD/SS
CHD/TC
CON/BC
CON/LET
CON/OW
CON/SS
CRF/CI
CU/SS
D/AP
D/GD
D/SG
D/SS
D/SS/OW
D/WL
DD/DEAF
DD/HN
DD/P
DD/SS
DD/SS/?PWS
DD/WG
DEAF/DD
DM/GD
DM/SG
DM/SS
LF
ALL
ALL
ALL
ALL
AML
AML
AN
AN
AN
ANX
ARR
ART
AS
AX
BP
C
CAR
CAR
CAR
CAH
CD
CD
CF
CF
CF
CHD
CHD
CHD
CON
CON
OW
SS
CRF
CU
D
D
D
o
D
D
DD
DD
DD
DD
DD
DD
DD
DM
DM
DM
DS/CHD DS
DS/DEAF DS
DS/DEP DS
DS/IP DS
DS/OW DS
DS/SG DS
DS/SS DS
DU/OW DU
DZ/V V
EB/SS BB
EN/?UTI EN
FTT/ABP FIT
FIT/Cl FIT
FIT/SS FIT
FIT/VO FIT
FTT/W FIT
GAU/SS GAU
GS/CAR CAR
HA/TN TN
HEMPAS/IO 10
HEP/WL HEP
HI/OW OW
HS/DZ HS
HS/MAL HS
HS/WL WL
HW/?DI HW
IDDM/?CD IDDM
IDDM/CAR IDDM
IODM/DEP IODM
IODM/DR IODM
IODM/GD IDDM
IODM/HT IDDM
IDDM/LET IDDM
IDDM/OE IDDM
IDDM/SG IODM
IODM/SS IDDM
IODM/TL IDDM
IDDM/WL IODM
JCA/?PAT lCA
lCA/SS JCA
LA/SS SS
LEAN/HA HA
LET/?AN LET
LET/COLD LET
LET/DZ LET
LET/HPHR HPHR
LET/MGL MGL
LET/P LET
LET/SPD SPD
LET/WG WC
LET/WK LET
LET/WL WL
MAC/SPD MAC
MEN/IP MEN
MEN/OW OW
NA/LET/DEP DEP
NO/SS NO
OW/?CS OW
OW/?PP OW
OW/ABP OW
OW/ANX OW
OW/CAT OW
OW/CON OW
OW/EAT OW
OW/GM OW
OW/HI OW
OW/HLD OW
OW/HS OW
OW/HT/SLOW OW
OW/IP OW
OW/PN OW
OW/SLOW OW
OW/SS SS
P/SS SS
PALE/SS SS
PDY/PU PU
PKU/SS PKU
PP/OW PP
PP/SG PP
PP/TALL PP
PWG/HA PWG
PWS/SS PWS
R/OW OW
RD/SS RD
SE/OW SE
SG/CAR CAR
SG/IDDM lOOM
SG/OW OW
SLE/PD SLE
SLE/SS SLE
SLOW/LET/WG WG
SLOWIOW/HN OW
SLOW/SS SS
SS/?DV SS
SS/ABP SS
SS/AML AML
SS/ANX SS
SS/ART ART
SS/AS AS
SS/BCH BCH
SS/COLD/FIT FTT
SS/CON SS
,. for diagnosis codes see Appendix B.
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SS/D D
SS/DBA SS
SS/DD DD
SS/DR SS
SS/DYS DYS
SS/EAT EAT
SS/BC SS
SS/EN SS
SS/BP BP
SS/FIT FIT
SS/GD SS
SS/Hr Hr .
SS/frV SS
SS/IDDM IDDM
SS/INF INF
SS/LET SS
SS/LU LU
SS/MB MB
SS/MD SS
SS/MYO MYO
SS/NO NO
SS/OP OP
SS/PD PD
SS/PP PP
SS/SLOW SS
SS/SLOW/CON SS
SS/THAL THAL
SS/TN SS
SS/TS TS
TALL/?AC TALL
TALL/?DBA TALL
TALL/ABA TALL
TALL/CLUMSY TALL
TALL/HA TALL
TC/RD RD
THAL/AP THAL
TN/S TN
TR/ANX ANX
TR/AT AT
TS/SG TS
TS/SS TS
UTI/LET/ AP UTI
UTI/WG/PDY UTI
VO/ABP VO
VO/SS VO
VO/WL VO
VSD/SS VSD
WG/LET WG
WG/QC QC
WK/AX AX
WL/AX AX
WL/LET WL
WL/P WL
WL/S WL
Secondary
SS/OW OW
OW/DD ow
OW/PP OW
OW/PD OW
OW/DEP OW
OW/MIP OW
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Patients aged less than 3 years
ALL/CON
APN/DD
CA/EAT/PWG
CAN/SAP
CF/HYP/TPN
CON/DD
CON/FIT
CON/WL
DD/CON
DD/FL
DO/HN
DD/MYO
DD/SD
DD/STRIDOR
DEAF/SS
DS/CON
DS/FIT
US/RN
DS/SS
FIT/CON
FIT/HA
FTT/HV
FIT/HYP
FIT/LAP
FTT/LET
FIT/MX
FIT/P
FTT/SLOW
FIT/SMALL
FTT/SS
GD/UH
HG/CON
RN/IR
HYP/INF
J/BA
J/CON
J/DS
J/EAT
J/MIP
J/PREM
LAF/FIT
LET/WL
MGL/DD
NO/SS
NYS/DD
OW/EAT
OW/P
PDA/SS
PREM/DR
PREM/FTT
PREM/J
ALL
DD
CA
CAN
CF
DD
FIT
WL
DD
DD
DD
DD
DD
DD
SS
DS
DS
DS
DS
FTI'
FTT
FIT
FIT
FIT
FIT
FIT
FIT
FIT
FIT
F1T
GD
HG
RN
INF
BA
J
DS
J
MIP
PREM
FIT
WL
DD
SS
DD
OW
OW
PDA
PREM
PREM
PREM
-1l2 -
PS/UH PS
PUO/S PUO
R/SS R
RSS/SS RSS
SB/FIT . SB
SB/OW/RN SB
SLOW/DD DD
SLOW/WG WG
SQ/DD DD
SS/AN AN
SS/BCH BCH
SS/CON SS
SS/DBA SS
SS/DD DD
SS/DD/HO DD
SS/FIT FIT
SS/HCAL HCAL
SS/SCH SCH
SS/SLOW SS
TALL/HA TALL
TIIAL/FIT TIIAL
UH/EAT EAT
UTI/FIT UTI
VO/FIT FTI'
VSD/FIT VSD
WG/UH WG
WL/CON WL
APPENDIXD
Fonnation of Diagnostic Groups"
Number in patients aged 3-11 years
1 SHORT STATURE
NON-ENDOCRINE
n 2IDDM n 30BESITY n
2A 3A
SS 1114 IDDM 395 OW 174
SG 15 D 34
SSG 13 DM 32 3B
GD 11 Ol 3 WG 8
MD 2 MOD 1
DW 0 NIDDM 0
GOlS 0
2B
IDDM 395
D 34
DM 32
MOD 1
NIDDM 0
.. for diagnosis codes see Appendix B.
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4 MALNUTRITION n STALL n 6HEART n
STATURE DISEASE
4A 4L SA 6A
FIT 46 PLE 0 TALL 63 TC 12
48 4M 58 68
CF 32 SCH 0 TALL 63 TC 12
RG 4 ARR 3
4C 4N (MAR) 3 AF 2
WL 31 SR 0 GIG 3 PALP 2
GS 3 BC 0
4D (SO) 1
AX 17 40 6C
UC 0 TC 12
4E CHD 4
EAT 6 4P ARR 3
W 0 AF 2
4F PALP 2
TN 5 CT 1
EB 1
4G BC 0
BS 2 FAL 0
4H
CD 2
41
MB 2
4J
PWG 2
4K
MNT 1
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7PUBERTALn 8 NEUROLOGICAL n 9 CONNECTIVE TISSUE n
DISORDERS DISORDERS DISEASE
7A DD 47 9A
pp 59 JCA 8
7B 9B
PD 39 JCA 8
MG 4
SLE 3
ID 2
DMY 1
]RA 1
SJS 1
RAY 0
SI 0
9C
ART 5
9D
JCA 8
ART 5
9E
MC 4
SLE 3
ID 2
DMY 1
JRA 1
SJS 1
RAY 0
SI 0
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10 BLOOD n 11 PSYCHOLOGICAL n 12 MENSTRUAL n
DISORDERS DISORDERS DISORDERS
lOA llA 12A
THAL 52 AN)( 4 VB 5
MEN 4
lOB lIB OM 4
AN 7 BD 3 IP 2
ACY 1
lOC llC PMS 1
AN 7 HA 4
SA 2 DEP 3 12B
DBD 1 AG 1 AM 3
GP 1 BAD 1 AM1 6
RCA 1 COF 1 AM2 8
PI 1
100 DV 0
HT 4
110
ANX 4
BD 3
HA 4
DEP 3
AG 1
BAD 1
COP 1
PI 1
DV 0
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13 NON-THYROIDAL n 14GENETIC n 15 LEUKAEMIAS n
ENDOCRINE DISEASES
DISORDERS
13A 14A 15A
GHD 50 TS 47 ALL 20
13B 14B 15B
cAB 19 DS 30 AML 5
13C 14C
GHD 50 ND 10
CAH 19
AD 5 140
CS 5 PWS 8
AI 1
PE 1 14E
AC 0 CN 6
ADR 0
HIN 0 14F
XXV 1
13D
CAH 19
AD 5
CS 5
AI 1
PE 1
AC 0
ADR 0
HIN 0
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16 LETHARGY n 17 HAIR n 18 DEAFNESS n 19CON n
DISORDERS
16A 17A DEAF 25 19A
LET 45 AP 21 CON 10
16B 178 19B
WK 5 HI 12 ABP 9
16C 19C
MAL 3 CON 10
ABP 9
160
LET 45 190
WK 5 DR 1
MAL 3
19B
CON 10
ABP 9
DR 1
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20 BONE n 21 MALE n 22 TREMOR n 23RENAL n
DISORDERS DEVELOPMENT DISEASE
20A 21A 22A CN 6
DBA 6 GM 10 TR 8 CRF 3
PBS 2
208 21B 22B RD 2
SE 9 HGO 6 S 7 UTI 2
IF 1
22C GL 0
TR/S 1 HI< 0
HUS 0
22D HYN 0
TR 8 N 0
S 7 NS 0
RC 0
RTA 0
VUR 0
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24NAUSEA/ n 25HEADn 26 RESPIRATORY n 27 MISCELLANEOUS n
VOMITING DISORDERS GROUP
V 6
24A 25A 26 OP 5
NA 3 SYN 6 AS 6 SSSFD 5
EN 4
248 258 (268) RPHR 4
VO 5 HS 6 AA 0 EO 3
HCAL 3
24C 25C INF 3
NA 3 DZ 0 MYO 3
VO 5 OH 3
PDY 3
PU 3
SB 3
ALL/HEPB '2.
BN '2.
CAT '2.
CU 2
ED 2
GAU 2
GRE 2
HO '2.
HR '2.
RV 2
IH 2
LP 2
PM '2.
R 2
SPD 2
SS/FSHD 2
WL/VO 2
ALC 1
AN/CAN 1
AT 1
AZ 1
B 1
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BCH 1 ES/ABP 1 LAC 1 SFR 1
BE 1 FOS 1 LEGSP 1 SG/SLOW 1
BE/WL 1 FH/COHD 1 LET/HS 1 SK 1
BLIDEAF 1 FIT/DD 1 LU 1 SLOW 1
BOILS 1 FIT/SS/HEPB 1 MA 1 SLOW/DH 1
BP 1 FU/HS 1 MAC 1 SMALL 1
BD 1 GAIT 1 MBD 1 SS/OW/HT 1
C 1 GAL 1 MGL 1 SS/WG 1
C 1 GAL 1 MIO 1 SSF/DD 1
CA 1 GD 1 MlP 1 ST/PWG 1
CAN 1 GM/SS 1 MMA 1 SVT 1
CE 1 GR 1 MMC 1 TAA/ABA 1
CF/CR 1 GR 1 MU/MQ 1 TALL/OW 1
CHD/DEAF 1 GRS/GD 1 MW 1 TC/EO 1
Cl 1 HCN 1 NL 1 TC/LET 1
CM 1 HE 1 NP 1 Ul 1
CO 1 HERNIA 1 CC 1 URTI 1
COH 1 HG 1 PA 1 VC PALSY 1
CY 1 HGHDEF 1 PALE/LET 1 VC-oE 1
D/UC 1 HOV 1 PC 1 VDRR 1
DCC 1 HR 1 PO/DD 1 VR 1
DD/AN 1 HS/?PDY 1 PF 1 VSD 1
DEAF/SLOW 1 HS/LET 1 PH 1 WL/?AX 1
DEP/AS 1 HSM 1 PKU 1 WL/AM 1
DGD 1 HU 1 PR/FIT 1 WL/DR 1
DH 1 HW 1 PT 1 WP 1
DI/GHD 1 lA 1 PUO 1
DL 1 ID/HEP 1 PV 1
DO 1 lODM/CD 1 QUIET/CON 1
DP 1 lHG 1 RN 1
DT 1 lM 1 RT 1
DU 1 10 1 SB/SS 1
DYS 1 lP/EO 1 SC 1
DYS/?V 1 IS 1 SDS 1
ER 1 lVA 1 SFE?/SFK 1
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APPENDIXE
Secondary Exclusion Criteria· Neurological Disorders excluded
Primary/Secondary Frequency Primary/Secondary Frequency
Diagnosis Code* Diagnosis Code*
MR 44 EP/MR 1
SS/MR 14 FTT/EP 1
SEI 13 HN/11R 1
HC 7 HPC 1
CNSD 4 MAC/MR 1
CP 4 MIC/DD 1
EP 4 MNG/DD 1
CC 3 11R/HGO 1
FIT/SEI 3 11R/OW 1
MIC/11R 3 MR/SD 1
QU 3 MR/SS 1
SOD 3 OW/11R 1
DD/MIC 2 PD/MR 1
DD/MR 2 PP/MR 1
GB 2 PP/SEl 1
MIC 2 PREM/MR 1
MR/AT 2 PWG/MR 1
SP 2 QU/SEl 1
SS/SEI 2 RC/AN/HN/MR 1
TSC 2 SEI/CP 1
ADD 1 SEl/DYS 1
AB 1 SS/DEAF/11R 1
CAR/SEl 1 SS/HC 1
CHD/HC 1 SS/MIC 1
CHOREA 1 SS/MR/PT 1
CP/SS 1 SS/OW/MR 1
DA 1 V/MR 1
DEAF/HP 1 WL/EP/11R 1
DI/MIC 1
EP 1
EP/CNSD 1 Total 160
*for diagnosis codes see Appendix B.
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APPENDIXF
Frequency of Diagnoses in patients aged less than 3 years of age
Diagnosis* Frequency Diagnosis Frequency Diagnosis Frequency
FIT 198 BC 2 CH 1
J 167 CAR 2 er 1
SS 121 CHD 2 CON/RP 1
DD 87 CO 2 CON/SLOW 1
DEAF 37 CON/LET 2 CON/VO 1
CON 33 DD/SS 2 CQ 1
HN 21 DPE 2 CRF 1
DS 16 DH 2 CY 1
IDDM 15 DS/HIP 2 DD/DYS 1
SC 12 FIT/MB 2 DD/MAC 1
pp 10 CAL 2 DD/MCL 1
PREM 10 HCO 2 DD/PP 1
FL 9 HPHR 2 DEAF/DD 1
HYP 9 HT 2 DM 1
MCL 9 res 2 DS/CHD 1
LAF 8 MB 2 DW 1
DBA 7 OE 2 EAT/LET/DR 1
AN 6 PR 2 EO 1
CD 6 PUO 2 EO/RE 1
MIP 6 SB 2 FIT/AN 1
SW 6 THAL 2 FIT/CA 1
CA 5 WC 2 FIT/INF 1
DYS 5 WK 2 FTT/IR/RE 1
EAT 5 ADR 1 FIT/I 1
FIT/DD 5 AN/FIT 1 FIT/PS 1
HA 5 AN/I 1 FIT/VO 1
HC 5 APN/BC 1 CEN 1
OW 5 APN/FIT 1 CHD 1
DI 4 AS/DD 1 Illi 1
AP 3 AT 1 HIN/CHD 1
CN 3 AY 1 HND 1
D 3 BA 1 HR 1
DR 3 BCH 1 HSM 1
HCAL 3 BH 1 HUS 1
LET 3 BI 1 HYN 1
OH 3 BR 1 IC 1
TALL 3 BR/VUR 1 INF 1
TS 3 CAN 1 IR 1
WL 3 CB 1 J/AN 1
ALL 2 CCHD 1 KY 1
AX 2 CF 1 LET/DR 1
*for diagnosis codes see Appendix B.
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Diagnosis Frequency Diagnosis Frequency
LET/DR/VO
LET/EAT
LF
MAC
MAP
MG
MGL/COARSE/LET
MGL/EAT
MGL/LET
MGL/SD
MN
MNT
MO
MYO
NH
NP
QC
OVE
PAT
PDA
PF
PLE
PS
PS/ALB
PWG
PWS
PY/ACS
R
RAY
RD
RSS
RTA
SAH
SCH
SD
SI
SIADH
SLOW/RN
SMALL
SOG
SPF
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
SS/AS/EC
SS/DEAF
SS/OW
SSG
SSSFD
SVT
TC
TN/RV
UTI
V
VC
VSD
VUR
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1
1
1
1
1
1
1
1
1
1
1
1
1
APPENDIXG
Frequency of Diagnoses encountered in patients aged 3 • 18 years
Diagnosis* Frequency Diagnosis Frequency Diagnosis Frequency
SS 1114 EAT 6 PDY 3
IDDM 395 HGO 6 PU 3
OW 169 HS 6 SB 3
TALL 63 SYN 6 SLE 3
pp 61 V 6 AF 2
TIIAL 52 AD 5 BN 2
GHD 50 AML 5 BS 2
DD 48 ART 5 C 2
TS 47 CS 5 CAT 2
FIT 46 HCH 5 CD 2
LET 45 OP 5 CU 2
PD 41 SSSFD 5 ED 2
D 34 TN 5 GAL 2
CF 32 VB 5 GAU 2
DM 32 VO 5 GR 2
WL 31 WK 5 GRE 2
DS 30 ANX 4 HCN 2
DEAF 25 CHD 4 HO 2
AP 21 EN 4 HR 2
ALL 20 HA 4 RV 2
CAR 19 RPHR 4 ID 2
AX 17 HT 4 rn: 2
SG 15 MEN 4 JP 2
SSG 13 MG 4 LP 2
HI 12 OM 4 MB 2
TC 12 RG 4 MD 2
GD 11 AM 3 PALP 2
CON 10 ARR 3 PBS 2
GM 10 BD 3 PM 2
ND 10 CRF 3 PWG 2
ABP 9 DEP 3 R 2
SE 9 DI 3 RD 2
AM2 8 EO 3 SA 2
JCA 8 GIG 3 SPD 2
PWS 8 GS 3 SS/FSHD 2
TR 8 HCAL 3 UTI 2
WG 8 INF 3 WL/VO 2
AN 7 MAL 3 AB 1
S 7 MAR 3 ACY 1
AMI 6 MYO 3 AG 1
AS 6 NA 3 AI 1
CN 6 OH 3 ALC 1
DBA 6 PB 3 ALL/HEPB 1
*for diagnosis codes see Appendix B.
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Diagnosis Frequency Diagnosis Frequency Diagnosis Frequency
AN/CAN 1 ER 1 MMA 1
AT 1 ES/ABP 1 MMC 1
AZ 1 FDS 1 MNT 1
B 1 PH/CORD 1 MOD 1
BAD 1 FIT/DD 1 MU/MQ 1
BCH 1 FIT/SS/HEP B 1 MW 1
BE 1 FU/HS 1 NL 1
BE/WL 1 GAIT 1 NP 1
BL/DEAF 1 GM/SS 1 QC 1
BOILS 1 GP 1 OW/DEP 1
BP 1 GRS/GD 1 OW/MIP 1
BU 1 HE 1 OW/PD 2
CA 1 HEP 1 PA 1
CAN 1 HERNIA 1 PALE/LET 1
CE 1 HG 1 PB/SS 1
CF/CR 1 HGHDEF 1 PC 1
CHD/DEAF 1 HOV 1 PD/DD 1
Cl 1 HS/LET 1 PE 1
CM 1 HSM 1 PF 1
CO 1 HU 1 PH 1
COF 1 HW 1 PI 1
COH 1 IA 1 PKU 1
CT 1 ID/HEP 1 PMS 1
CY 1 IDDM/CD 1 PR/FTI 1
D/UC 1 IF 1 PT 1
DBD 1 IHG 1 PUO 1
DCC 1 IM 1 PV 1
DD/AN 1 IO 1 QUIET/CON 1
DEAF/SLOW 1 lP/EO 1 RCA 1
DEP/AS 1 IS 1 RN 1
DGD 1 ]RA 1 RT 1
DH 1 JVA 1 SB/SS 1
DI/GHD 1 LAC 1 se 1
DL 1 LEGSP 1 SDS 1
DMY 1 LET/HS 1 SFR 1
00 1 LF 1 SG/SLOW 1
DP 1 LU 1 SJS 1
DR 1 MA 1 SK 1
DT 1 MAC 1 SLOW 1
DU 1 MBD 1 SLOW/DH 1
DYS 1 MGL 1 SMALL 1
DYS/?V 1 MIO 1 SO 1
EB 1 MIP 1 SS/OW/HT 1
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Diagnosis Frequency
SS/WG 1
SSF/DD 1
ST/PWG 1
SVT 1
TAA/ABA 1
TALL/OW 1
TC/EO 1
TC/LET 1
TR/S 1
UI 1
URTI 1
VC PALSY 1
VC-GE 1
VDRR 1
VR 1
VSD 1
WL/AM 1
WL/DR 1
WP 1
XXY 1
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